_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
503220987,7/15/2014 10:08:57,,1323476006,7/15/2014 10:08:42,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[LOCATION],[LOCATION],SKIN LICHENOID ERUPTION,n/a,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 11:06:05,,1323513726,7/15/2014 11:05:49,instagc,1,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],examination of the,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 11:32:23,,1323530817,7/15/2014 11:31:48,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,[LOCATION],[LOCATION],was consistent with,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 11:42:24,,1323536756,7/15/2014 11:40:59,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN LICHENOID ERUPTION,n/a,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 12:31:14,,1323558447,7/15/2014 12:30:06,paiddailysurveys,1,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SKIN consistent LICHENOID ERUPTION,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 12:38:25,,1323561179,7/15/2014 12:38:03,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examination of SKIN was consistent with LICHENOID ERUPTION,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 12:42:01,,1323562432,7/15/2014 12:40:59,prodege,1,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],examination of,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 12:43:32,,1323563024,7/15/2014 12:42:52,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,[LOCATION],[LOCATION],examination of,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 13:14:26,,1323574994,7/15/2014 13:13:42,neodev,1,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],was consistent with a LICHENOID ERUPTION in all cases.,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 14:04:33,,1323590916,7/15/2014 14:03:45,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,[LOCATION],[LOCATION],of the,n/a,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 14:11:49,,1323592879,7/15/2014 14:11:17,elite,1,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",was consistent with,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 14:20:09,,1323595304,7/15/2014 14:19:55,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,[LOCATION],[LOCATION],of,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 14:50:57,,1323606126,7/15/2014 14:50:31,clixsense,1,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examination of,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 16:32:57,,1323681294,7/15/2014 16:32:10,clixsense,1,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],examination,N/A,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220987,7/15/2014 16:56:48,,1323708294,7/15/2014 16:56:21,instagc,1,26784981,USA,CA,San Francisco,73.32.39.90,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]
[SYMPTOM]",consistent,NA,32,59,35,77,1,RO-has_finding_site,905296-FS1,Histological examination of the SKIN was consistent with a LICHENOID ERUPTION in all cases.,SKIN,LICHENOID ERUPTION
503220988,7/15/2014 10:10:21,,1323476710,7/15/2014 10:09:49,vivatic,1,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],part of the spectrum,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 10:17:50,,1323481276,7/15/2014 10:17:26,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may represent,na,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 11:07:06,,1323514791,7/15/2014 11:06:23,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may represent part,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 11:24:42,,1323526505,7/15/2014 11:24:26,bitcoinget,1,25255063,GBR,V2,Glasgow,86.174.15.198,[PART_OF],[PART_OF],part of,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 11:58:55,,1323546325,7/15/2014 11:58:37,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],represent part,n/a,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 12:21:35,,1323554926,7/15/2014 12:20:56,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[PART_OF],[PART_OF],SLE ACUTE LUPUS PNEUMONITIS,n/a,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 12:24:57,,1323556174,7/15/2014 12:23:42,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],part of the spectrum of,n/a,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 12:25:42,,1323556461,7/15/2014 12:24:39,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],part of the spectrum of,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 14:29:27,,1323598021,7/15/2014 14:29:15,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],represent,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 14:57:16,,1323608617,7/15/2014 14:56:06,quickrewards,1,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],part of the spectrum,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 15:16:45,,1323617726,7/15/2014 15:16:06,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Separate conditions,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 15:35:41,,1323630521,7/15/2014 15:35:20,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 16:00:00,,1323648930,7/15/2014 15:59:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],part of the spectrum of,n/a,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 16:14:13,,1323660363,7/15/2014 16:13:26,clixsense,1,19500241,USA,NC,Greensboro,174.98.255.13,[NONE],[NONE],N/A,There is no association between the two words.,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220988,7/15/2014 16:46:15,,1323696720,7/15/2014 16:45:40,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],hemorrhage occurs,N/A,113,67,135,70,-1,RO-has_manifestation,906387-FS1,Alveolar hemorrhage occurs in approximately 2% 4% of patients with SLE and may represent part of the spectrum of ACUTE LUPUS PNEUMONITIS (tvml 10tvml ; tvml 32tvml.,ACUTE LUPUS PNEUMONITIS,SLE
503220989,7/15/2014 10:01:27,,1323470867,7/15/2014 10:00:30,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],With respect to in cases of,N/a,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 11:08:06,,1323515688,7/15/2014 11:07:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],fronto nasal approach exposing frontal base skull.,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 11:15:07,,1323520711,7/15/2014 11:14:37,prodege,1,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cases of,n/a,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 11:18:28,,1323522997,7/15/2014 11:17:53,prodege,1,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],in cases of,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 11:33:04,,1323531191,7/15/2014 11:32:24,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],appeared to be,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 11:54:32,,1323544080,7/15/2014 11:54:08,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS,n/a,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 12:28:17,,1323557379,7/15/2014 12:27:15,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in cases of,n/a,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 12:29:37,,1323557894,7/15/2014 12:29:03,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ATROPHIC BRAIN HYDROCEPHALUS,n/a,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 12:41:32,,1323562269,7/15/2014 12:40:34,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],in cases of HYDROCEPHALUS,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 13:11:51,,1323574154,7/15/2014 13:11:40,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],in cases of,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 13:20:27,,1323577053,7/15/2014 13:20:03,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],in cases of,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 13:30:57,,1323580558,7/15/2014 13:30:30,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],cases,na,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 13:53:29,,1323587776,7/15/2014 13:53:00,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[LOCATION],[LOCATION],in,none,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 14:29:03,,1323597931,7/15/2014 14:28:55,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],approach,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220989,7/15/2014 14:56:06,,1323608106,7/15/2014 14:54:57,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],in cases of,N/A,20,47,33,60,1,RO-disease_has_primary_anatomic_site,902065-FS1,With respect to the ATROPHIC BRAIN in cases of HYDROCEPHALUS the fronto nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.,ATROPHIC BRAIN,HYDROCEPHALUS
503220990,7/15/2014 09:54:31,,1323464999,7/15/2014 09:52:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,"MOPP is the treatment for Hodgkins, not myeloma",227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 10:08:46,,1323475927,7/15/2014 10:08:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated with,N/A,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 10:19:16,,1323482357,7/15/2014 10:19:00,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],treated with,N/A,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 11:17:46,,1323522517,7/15/2014 11:17:10,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],treated with,not applicable,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 12:00:47,,1323547180,7/15/2014 12:00:14,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],treated with,n/a,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 12:14:18,,1323552043,7/15/2014 12:13:32,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[TREATS],[TREATS],treated with MELPHALAN,MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 12:15:41,,1323552573,7/15/2014 12:15:21,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],treated with,N/a,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 12:33:43,,1323559347,7/15/2014 12:32:16,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],treated with,is treated by,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 12:52:21,,1323566771,7/15/2014 12:51:49,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],treated,N/A,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 13:25:11,,1323578676,7/15/2014 13:24:21,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treated with,na,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 13:49:29,,1323586606,7/15/2014 13:48:54,elite,1.0,28276268,USA,CA,San Rafael,98.210.32.37,[TREATS],[TREATS],treated with,[TREATS],227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 14:22:11,,1323595835,7/15/2014 14:21:59,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treated,N/A,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 15:05:43,,1323612335,7/15/2014 15:05:13,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],treated with MELPHALAN,N/A,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 15:34:29,,1323629710,7/15/2014 15:33:53,instagc,1,19636746,USA,NY,Andover,192.182.216.225,[TREATS],[TREATS],treated,na,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220990,7/15/2014 15:44:04,,1323636890,7/15/2014 15:43:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MULTIPLE MYELOMA MELPHALAN,n/a,227,276,242,285,1,RO-may_treat,908204-FS1,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer treated with MELPHALAN",MULTIPLE MYELOMA,MELPHALAN
503220991,7/15/2014 10:00:29,,1323470025,7/15/2014 09:59:46,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[IS_A]",Studies have established relationships between,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 10:12:56,,1323478118,7/15/2014 10:12:32,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",relationships between,na,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 11:19:59,,1323523935,7/15/2014 11:19:04,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],have established,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 11:26:21,,1323527277,7/15/2014 11:25:26,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are not associated with each other.,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 11:52:21,,1323542810,7/15/2014 11:51:56,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EPILEPSY SEIZURES,n/a,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 12:18:42,,1323553719,7/15/2014 12:18:07,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EPILEPSY SEIZURES,n/a,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 12:26:50,,1323556923,7/15/2014 12:25:43,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relationships between,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 12:52:07,,1323566655,7/15/2014 12:51:48,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],EPILEPSY,dsaw,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 13:06:01,,1323572058,7/15/2014 13:05:22,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],have established relationships between,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 14:20:25,,1323595377,7/15/2014 14:20:14,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relationships between,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 14:21:59,,1323595792,7/15/2014 14:21:30,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],have established relationships between,[ASSOCIATED_WITH],123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 14:28:17,,1323597710,7/15/2014 14:28:09,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],have,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 14:43:45,,1323603317,7/15/2014 14:43:11,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],relationships between,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 15:14:32,,1323616524,7/15/2014 15:12:50,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],Studies of EPILEPSY have established relationships between SEIZURES,N/A,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220991,7/15/2014 16:04:44,,1323652769,7/15/2014 16:04:15,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],with SEIZURES,n/a,123,75,130,83,-1,RO-has_definitional_manifestation,904640-FS1,"Studies of human patients with temporal lobe epilepsy and animal models of EPILEPSY have established relationships between SEIZURES excitotoxic hippocampal damage, and memory impairment.",SEIZURES,EPILEPSY
503220992,7/15/2014 10:50:20,,1323503248,7/15/2014 10:49:23,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],with,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 10:58:07,,1323508297,7/15/2014 10:57:27,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],was observed in with,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 11:14:47,,1323520514,7/15/2014 11:14:21,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 11:29:14,,1323529030,7/15/2014 11:28:24,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],was observed in 5 out of 6 patients with,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 11:51:09,,1323541828,7/15/2014 11:50:21,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOCYTOSIS ESSENTIAL THROMBOCYTHEMIA,n/a,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 12:36:44,,1323560503,7/15/2014 12:34:42,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],with,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 13:49:14,,1323586571,7/15/2014 13:47:43,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[SYMPTOM],[SYMPTOM],in 5 out of 6 patients with,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 14:10:58,,1323592712,7/15/2014 14:10:30,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",was observed in,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 14:50:04,,1323605851,7/15/2014 14:49:41,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],Improvement of,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 14:57:54,,1323608819,7/15/2014 14:57:17,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],reduction of in patients with,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 15:35:06,,1323630075,7/15/2014 15:34:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THROMBOCYTOSIS ESSENTIAL THROMBOCYTHEMIA,n/a,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 15:52:09,,1323642981,7/15/2014 15:51:43,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],was observed in,n/a,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 16:10:11,,1323657075,7/15/2014 16:07:37,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was observed,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 16:12:01,,1323658618,7/15/2014 16:11:26,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],reduction of,n/a,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220992,7/15/2014 16:35:20,,1323683949,7/15/2014 16:34:38,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],observed observed,N/A,100,156,113,181,-1,RO-disease_has_finding,901650-FS1,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of THROMBOCYTOSIS was observed in 5 out of 6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503220993,7/15/2014 09:55:59,,1323466135,7/15/2014 09:55:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],developed,na,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 10:16:04,,1323480104,7/15/2014 10:15:45,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[CAUSES],[CAUSES],who developed,na,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 10:47:07,,1323500887,7/15/2014 10:45:44,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],developed,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 11:15:57,,1323521206,7/15/2014 11:15:33,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],who developed,n/a,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 11:22:26,,1323525150,7/15/2014 11:21:53,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],developed,not applicable,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 11:27:04,,1323527744,7/15/2014 11:26:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],who developed,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 11:28:12,,1323528524,7/15/2014 11:26:58,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [CONTRAINDICATES] [CAUSES],"[CAUSES]
[SYMPTOM]
[CONTRAINDICATES]",developed,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 11:43:01,,1323537119,7/15/2014 11:42:26,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[CAUSES],[CAUSES],COBALAMIN DEFICIENCY SUBACUTE COMBINED DEGENERATION OF THE SPINAL,n/a,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 11:47:15,,1323539452,7/15/2014 11:46:25,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with unsuspected who developed,n/a,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 12:39:11,,1323561508,7/15/2014 12:38:26,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 13:17:34,,1323576064,7/15/2014 13:17:06,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],who developed,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 13:28:16,,1323579753,7/15/2014 13:27:59,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[MANIFESTATION],[MANIFESTATION],who developed,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 14:00:50,,1323589985,7/15/2014 14:00:29,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",developed,none,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 14:14:37,,1323593574,7/15/2014 14:13:54,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",who developed,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220993,7/15/2014 14:28:27,,1323597744,7/15/2014 14:28:17,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],developed,N/A,74,39,117,59,1,RO-cause_of,900320-FS1,We describe a patient with unsuspected COBALAMIN DEFICIENCY who developed SUBACUTE COMBINED DEGENERATION OF THE SPINAL cord after nitrous oxide anesthesia.,SUBACUTE COMBINED DEGENERATION OF THE SPINAL,COBALAMIN DEFICIENCY
503220994,7/15/2014 10:03:02,,1323472094,7/15/2014 10:02:17,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],can later lead to,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 10:03:57,,1323472819,7/15/2014 10:03:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],can later lead to,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 10:09:51,,1323476550,7/15/2014 10:09:37,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[CAUSES],[CAUSES],later lead to,na,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 11:03:24,,1323511503,7/15/2014 11:02:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],can later lead to,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 11:04:29,,1323512300,7/15/2014 11:04:19,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 11:20:30,,1323524196,7/15/2014 11:19:44,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],can later lead,n/a,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 11:23:37,,1323525867,7/15/2014 11:23:09,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],can later lead to,not applicable,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 11:30:44,,1323529875,7/15/2014 11:30:16,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],can later lead to,n/a,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 11:34:05,,1323531857,7/15/2014 11:33:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],can later lead to,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 12:20:04,,1323554303,7/15/2014 12:19:27,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],MICRONUTRIENT DEFICITS PROTEIN CALORIE MALNUTRITION,n/a,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 12:43:14,,1323562894,7/15/2014 12:42:33,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],lead to,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 13:15:04,,1323575184,7/15/2014 13:14:27,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CAUSES],[CAUSES],Selective food intake can later lead,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 13:30:00,,1323580293,7/15/2014 13:29:31,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [LOCATION],"[CAUSES]
[LOCATION]",later lead to,na,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 13:47:32,,1323586107,7/15/2014 13:47:12,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[ASSOCIATED_WITH],[ASSOCIATED_WITH],can later lead to,N/A,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220994,7/15/2014 14:10:17,,1323592526,7/15/2014 14:09:48,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[PREVENTS],[PREVENTS],lead,none,101,30,128,52,-1,RO-cause_of,900167-FS1,Selective food intake induced MICRONUTRIENT DEFICITS (moderate undernutrition) and can later lead to PROTEIN CALORIE MALNUTRITION (PCM.,PROTEIN CALORIE MALNUTRITION,MICRONUTRIENT DEFICITS
503220995,7/15/2014 10:09:48,,1323476520,7/15/2014 10:08:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,the association is something else within the sentence.,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 10:16:00,,1323480083,7/15/2014 10:15:26,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Absolutely no relationship between the two words.,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 10:54:06,,1323505899,7/15/2014 10:53:11,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,No related lik between these terms in this sentence,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 11:00:48,,1323509788,7/15/2014 10:59:36,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,association is not a medical term,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 11:04:06,,1323511986,7/15/2014 11:03:52,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATION,n/a,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 11:25:46,,1323527064,7/15/2014 11:25:27,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,NO CLEAR RELATIONSHIP.,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 11:35:21,,1323532610,7/15/2014 11:33:35,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[PART_OF],[PART_OF],ASSOCIATION of,n/a,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 11:43:14,,1323537217,7/15/2014 11:42:42,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,there is no direct link between these two words,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 11:55:12,,1323544356,7/15/2014 11:54:21,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],overweight or,n/a,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 12:12:57,,1323551482,7/15/2014 12:12:40,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATION child overweight,N/a,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 12:23:10,,1323555502,7/15/2014 12:22:28,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATION OBESITY,n/a,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 12:57:55,,1323568790,7/15/2014 12:57:39,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],ASSOCIATION,asd,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 13:50:28,,1323586857,7/15/2014 13:49:46,elite,1.0,28276268,USA,CA,San Rafael,98.210.32.37,[CAUSES],[CAUSES],of child overweight,[CAUSES],12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 14:28:45,,1323597868,7/15/2014 14:28:28,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASSOCIATION,N/A,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220995,7/15/2014 14:32:32,,1323598986,7/15/2014 14:31:55,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[NONE],[NONE],N/A,Irrelevant in medical terms,12,47,22,54,-1,RO-has_definitional_manifestation,904767-FS1,Data on the ASSOCIATION of child overweight or OBESITY with levels of attendance are too sparse to draw conclusions.,ASSOCIATION,OBESITY
503220996,7/15/2014 10:06:18,,1323474584,7/15/2014 10:05:53,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[TREATS],[TREATS],treatment of,na,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 10:15:01,,1323479403,7/15/2014 10:14:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treatment,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 10:35:58,,1323493097,7/15/2014 10:34:47,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],treatment,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 11:28:16,,1323528570,7/15/2014 11:28:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for the treatment of,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 12:05:15,,1323548774,7/15/2014 12:04:58,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],the treatment of,n/a,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 12:17:07,,1323553123,7/15/2014 12:15:52,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],treatment,INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 12:38:01,,1323560991,7/15/2014 12:37:44,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],INTRAVAGINAL 0.75% METRONIDAZOLE GEL for treatment of BACTERIAL VAGINOSIS,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 12:46:29,,1323564283,7/15/2014 12:45:40,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],treatment,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 14:28:34,,1323597783,7/15/2014 14:28:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],0.75%,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 14:29:46,,1323598100,7/15/2014 14:29:34,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],for the treatment of,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 15:24:34,,1323622586,7/15/2014 15:24:03,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treatment of,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 15:52:29,,1323643225,7/15/2014 15:52:09,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n\a,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 16:05:52,,1323653736,7/15/2014 16:05:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment,n/a,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 16:38:24,,1323687736,7/15/2014 16:38:05,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],treatment,N/A,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220996,7/15/2014 16:46:26,,1323696872,7/15/2014 16:45:42,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],treatment,n/a,114,56,132,92,1,RO-may_treat,907884-FS1,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of INTRAVAGINAL 0.75% METRONIDAZOLE GEL for the treatment of BACTERIAL VAGINOSIS",BACTERIAL VAGINOSIS,INTRAVAGINAL 0.75% METRONIDAZOLE GEL
503220997,7/15/2014 10:15:23,,1323479754,7/15/2014 10:15:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 10:32:31,,1323490853,7/15/2014 10:31:25,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FACTOR VIII; HEMOPHILIA A,Associated With,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 11:11:37,,1323518458,7/15/2014 11:11:16,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],deficiency of,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 11:35:39,,1323532755,7/15/2014 11:35:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 11:42:11,,1323536644,7/15/2014 11:41:38,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,this sentence makes no sense to me at all,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 11:59:15,,1323546453,7/15/2014 11:58:57,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 12:42:50,,1323562755,7/15/2014 12:40:57,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],deficiency of,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 13:13:01,,1323574479,7/15/2014 13:12:37,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 13:54:29,,1323588038,7/15/2014 13:52:52,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],associated with,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 14:03:03,,1323590551,7/15/2014 14:01:02,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 14:22:48,,1323596023,7/15/2014 14:22:31,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 15:19:26,,1323619191,7/15/2014 15:18:56,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],in patients with,n/a,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 16:40:56,,1323690768,7/15/2014 16:40:24,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[PREVENTS],[PREVENTS],A Prevention,N/A,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 16:58:14,,1323709950,7/15/2014 16:57:22,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],can't,no relation mentioned,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220997,7/15/2014 17:04:53,,1323717006,7/15/2014 17:03:57,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[PREVENTS],[PREVENTS],Prevention control,n/a,372,185,383,196,1,RO-may_treat,907524-FS1,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); FACTOR VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with HEMOPHILIA A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",HEMOPHILIA A,FACTOR VIII
503220998,7/15/2014 10:00:57,,1323470544,7/15/2014 10:00:43,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring,na,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 10:15:45,,1323479957,7/15/2014 10:15:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 10:16:29,,1323480335,7/15/2014 10:16:01,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:08:47,,1323516240,7/15/2014 11:07:47,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[MANIFESTATION],[MANIFESTATION],requiring,not applicable,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:26:49,,1323527600,7/15/2014 11:26:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:29:22,,1323529090,7/15/2014 11:28:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SIDE_EFFECT],[SIDE_EFFECT],had requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:29:29,,1323529110,7/15/2014 11:29:13,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:33:34,,1323531504,7/15/2014 11:33:11,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],requiring,n/a,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:38:11,,1323534229,7/15/2014 11:37:35,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS EXTRACTION OF BOTH LENSES,n/a,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 11:53:15,,1323543476,7/15/2014 11:51:15,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SIDE_EFFECT],[SIDE_EFFECT],history of requiring,n/a,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 12:16:10,,1323552757,7/15/2014 12:15:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],requiring,N/a,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 12:35:41,,1323560053,7/15/2014 12:34:30,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 12:56:17,,1323568128,7/15/2014 12:56:01,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS,asd,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 13:06:46,,1323572324,7/15/2014 13:06:35,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],requiring,N/A,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220998,7/15/2014 13:41:25,,1323584228,7/15/2014 13:40:58,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],requiring,na,75,20,99,64,1,RO-has_finding_site,905467-FS1,He had a history of SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS requiring EXTRACTION OF BOTH LENSES and operatively corrected genu valgum on both sides.,EXTRACTION OF BOTH LENSES,SEVERE OLIGOPHRENIA BILATERAL ECTOPIA LENTIS
503220999,7/15/2014 10:09:37,,1323476408,7/15/2014 10:09:16,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],could still have,na,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 10:15:24,,1323479763,7/15/2014 10:14:40,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],in the group that could still have,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 10:33:11,,1323491273,7/15/2014 10:32:32,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],VENTRICULAR TACHYCARDIA still have TACHYCARDIA,Is A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 11:03:49,,1323511806,7/15/2014 11:03:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],VENTRICULAR TACHYCARDIA TACHYCARDIA,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 11:12:14,,1323518942,7/15/2014 11:11:55,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],that could still have,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 11:23:43,,1323525914,7/15/2014 11:23:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],TACHYCARDIA,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 11:51:06,,1323541790,7/15/2014 11:49:44,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the group that could still have provoked.,n/a,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 12:13:06,,1323551553,7/15/2014 12:12:33,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],still have,n/a,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 12:44:31,,1323563464,7/15/2014 12:43:55,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],group that could still have,is a type of,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 12:51:47,,1323566542,7/15/2014 12:50:13,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],provoked.,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 13:25:43,,1323578801,7/15/2014 13:25:13,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],provoked.,na,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 14:28:59,,1323597899,7/15/2014 14:28:46,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the group,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 14:29:59,,1323598165,7/15/2014 14:29:50,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],provoked.,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 15:15:31,,1323617046,7/15/2014 15:14:59,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],TACHYCARDIA,N/A,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503220999,7/15/2014 15:37:10,,1323631703,7/15/2014 15:35:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",VENTRICULAR TACHYCARDIA TACHYCARDIA,n/a,143,131,153,154,-1,RO-has_definitional_manifestation,904775-FS1,"D sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the VENTRICULAR TACHYCARDIA in the group that could still have TACHYCARDIA provoked.",TACHYCARDIA,VENTRICULAR TACHYCARDIA
503221000,7/15/2014 09:58:54,,1323468816,7/15/2014 09:57:15,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,"The two words are no related in this sentence. Dedifferentiation is made between this and another condition, not referenced in the sentence.",0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 10:06:42,,1323474784,7/15/2014 10:05:36,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],DEDIFFERENTIATION to,N/A,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 10:17:24,,1323481072,7/15/2014 10:17:07,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of astrocytoma to,na,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 11:16:15,,1323521431,7/15/2014 11:15:52,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of to,N/A,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 11:22:32,,1323525212,7/15/2014 11:22:08,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],to,N/A,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 11:43:29,,1323537451,7/15/2014 11:43:04,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",DEDIFFERENTIATION GLIOBLASTOMA,n/a,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 12:15:12,,1323552425,7/15/2014 12:12:52,prodege,1,11864493,GBR,Z4,Wrexham,212.219.196.69,[OTHER],[OTHER],of astrocytoma to,N/A,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 12:17:03,,1323553058,7/15/2014 12:16:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],of,N/a,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 12:33:04,,1323559124,7/15/2014 12:32:32,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DEDIFFERENTIATION GLIOBLASTOMA,n/a,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 12:38:40,,1323561234,7/15/2014 12:36:45,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],n/a,it is unclear,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 12:48:57,,1323565483,7/15/2014 12:48:43,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],DEDIFFERENTIATION of,dsa,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 13:02:27,,1323570815,7/15/2014 13:01:52,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,Na,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 13:05:23,,1323571764,7/15/2014 13:04:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],of astrocytoma to therapy are discussed.,N/A,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 14:04:58,,1323591043,7/15/2014 14:04:18,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[CAUSES],[CAUSES],astrocytoma to,[CAUSES],0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221000,7/15/2014 14:41:38,,1323602498,7/15/2014 14:41:03,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],radiation therapy,N/A,0,36,16,48,1,RO-disease_has_finding,901662-FS1,DEDIFFERENTIATION of astrocytoma to GLIOBLASTOMA and the role of radiation therapy are discussed.,DEDIFFERENTIATION,GLIOBLASTOMA
503221001,7/15/2014 10:17:24,,1323481042,7/15/2014 10:17:05,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],results from infection,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 10:58:49,,1323508700,7/15/2014 10:58:09,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],results from infection with,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 11:14:16,,1323520219,7/15/2014 11:11:38,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[MANIFESTATION],[MANIFESTATION],results,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 11:39:52,,1323535159,7/15/2014 11:39:14,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[CAUSES],[CAUSES],ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS HEPATITIS B VIRUS,n/a,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 11:45:24,,1323538418,7/15/2014 11:44:50,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[CAUSES],[CAUSES],results from infection with,n/a,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 11:53:53,,1323543832,7/15/2014 11:53:32,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],results from,n/a,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 12:12:22,,1323551210,7/15/2014 12:11:50,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B HEPATITIS B VIRUS,n/a,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 12:38:52,,1323561349,7/15/2014 12:37:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],results from,n/a,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 13:57:40,,1323589011,7/15/2014 13:57:11,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],results from infection with,n/a,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 14:29:12,,1323597961,7/15/2014 14:29:00,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],results from infection,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 14:30:36,,1323598379,7/15/2014 14:30:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],HEPATITIS B,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 15:06:02,,1323612493,7/15/2014 15:05:43,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[CAUSES],[CAUSES],results from infection with,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 15:29:52,,1323626352,7/15/2014 15:29:30,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],results from infection,N/A,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 15:36:29,,1323631195,7/15/2014 15:34:30,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,[CAUSES],[CAUSES],results from infection,na,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221001,7/15/2014 16:41:59,,1323691877,7/15/2014 16:40:55,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],results,?,85,14,101,56,1,RO-has_causative_agent,903602-FS1,Hepatitis B e ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B results from infection with HEPATITIS B VIRUS mutants unable to produce HBeAg.,HEPATITIS B VIRUS,ANTIGEN HBEAG NEGATIVE CHRONIC HEPATITIS B
503221002,7/15/2014 10:01:56,,1323471179,7/15/2014 10:00:14,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],as did patients with,N/A,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 10:09:52,,1323476558,7/15/2014 10:09:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 10:37:39,,1323494120,7/15/2014 10:37:01,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],TENSION HEADACHE HEADACHE,Is A,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 11:14:35,,1323520435,7/15/2014 11:14:05,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 11:23:54,,1323526079,7/15/2014 11:23:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],HEADACHE,N/A,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 11:53:45,,1323543734,7/15/2014 11:53:12,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TENSION HEADACHE HEADACHE,n/a,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 11:57:51,,1323545771,7/15/2014 11:57:15,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],post traumatic headache and associated,n/a,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 12:10:11,,1323550469,7/15/2014 12:09:20,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,both are examples,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 12:28:59,,1323557639,7/15/2014 12:28:18,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],patients with and,different types of headaches,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 12:29:14,,1323557741,7/15/2014 12:28:39,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Tension headache is a type of headache,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 13:30:42,,1323580508,7/15/2014 13:30:26,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],and,N/A,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 13:36:38,,1323582564,7/15/2014 13:36:12,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,na,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 14:08:23,,1323591904,7/15/2014 14:07:39,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,[ASSOCIATED_WITH],88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 15:22:15,,1323621005,7/15/2014 15:21:48,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEADACHE,N/A,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221002,7/15/2014 16:11:24,,1323658097,7/15/2014 16:11:09,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],HEADACHE,n/a,88,80,95,96,-1,RO-has_definitional_manifestation,904659-FS1,Patients with migraine did not respond to placebos as well as did patients with TENSION HEADACHE post traumatic headache and HEADACHE associated with hypertension.,HEADACHE,TENSION HEADACHE
503221003,7/15/2014 09:59:19,,1323469168,7/15/2014 09:59:03,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],suggest,na,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 11:05:56,,1323513576,7/15/2014 11:05:36,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],suggest,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 11:11:25,,1323518347,7/15/2014 11:11:04,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],suggest,n/a,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 11:16:43,,1323521673,7/15/2014 11:15:58,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],suggest,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 11:21:15,,1323524589,7/15/2014 11:20:45,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],sore throat diffuse suggest,not applicable,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 11:51:52,,1323542360,7/15/2014 11:51:13,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],ADENOPATHY INFECTIOUS MONONUCLEOSIS,n/a,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 12:18:46,,1323553748,7/15/2014 12:18:32,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],suggest,N/a,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 12:32:15,,1323558745,7/15/2014 12:30:03,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],suggest,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 13:35:32,,1323582155,7/15/2014 13:35:03,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM],[SYMPTOM],suggest,na,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 13:48:52,,1323586514,7/15/2014 13:48:15,elite,1.0,28276268,USA,CA,San Rafael,98.210.32.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],suggest,[DIAGNOSE_BY_TEST_OR_DRUG],34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 14:31:48,,1323598778,7/15/2014 14:31:38,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],viral,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 15:08:22,,1323613451,7/15/2014 15:08:00,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 15:17:08,,1323617904,7/15/2014 15:16:45,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],suggest,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 16:11:07,,1323657859,7/15/2014 16:10:50,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],suggest,n/a,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221003,7/15/2014 16:12:11,,1323658755,7/15/2014 16:11:44,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suggest,N/A,34,53,43,77,1,RO-disease_has_finding,901789-FS1,Prodromal sore throat and diffuse ADENOPATHY suggest INFECTIOUS MONONUCLEOSIS rather than viral hepatitis.,ADENOPATHY,INFECTIOUS MONONUCLEOSIS
503221004,7/15/2014 10:14:39,,1323479211,7/15/2014 10:14:15,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Two different conditions.,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 10:20:36,,1323483249,7/15/2014 10:18:57,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[OTHER],[OTHER],was significantly higher than in,na,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 11:18:12,,1323522795,7/15/2014 11:17:33,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],than in,n/a,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 11:19:29,,1323523586,7/15/2014 11:18:46,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are two different types of lesions.,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 11:29:48,,1323529279,7/15/2014 11:29:29,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],than in,N/A,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 11:47:24,,1323539562,7/15/2014 11:46:43,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DELAYED TYPE HYPERSENSITIVITY LESIONS EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,n/a,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 11:52:59,,1323543286,7/15/2014 11:52:36,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,not enough info given to find a relation,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 12:11:44,,1323551017,7/15/2014 12:10:57,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DELAYED TYPE HYPERSENSITIVITY LESIONS EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,n/a,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 12:31:36,,1323558554,7/15/2014 12:30:56,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],significantly higher than in,different kinds of lesions,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 12:39:33,,1323561630,7/15/2014 12:38:38,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],EXPERIMENTAL,N/A,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 13:42:42,,1323584661,7/15/2014 13:42:04,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],significantly higher,na,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 13:50:47,,1323586926,7/15/2014 13:49:48,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,it's a comparison,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 14:19:46,,1323595161,7/15/2014 14:19:19,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],than,N/A,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 14:23:17,,1323596165,7/15/2014 14:22:44,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[MANIFESTATION]",was significantly higher than,[DIAGNOSE_BY_TEST_OR_DRUG] [MANIFESTATION],87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221004,7/15/2014 14:55:35,,1323607877,7/15/2014 14:55:13,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],significantly higher than,N/A,87,16,133,53,-1,RO-cause_of,900459-FS1,Their number in DELAYED TYPE HYPERSENSITIVITY LESIONS was significantly higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS.,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS LESIONS,DELAYED TYPE HYPERSENSITIVITY LESIONS
503221005,7/15/2014 09:55:29,,1323465721,7/15/2014 09:55:15,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],include,na,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 10:17:41,,1323481229,7/15/2014 10:17:24,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Most common,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 11:11:37,,1323518463,7/15/2014 11:10:42,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 11:24:13,,1323526255,7/15/2014 11:23:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 12:02:40,,1323547857,7/15/2014 12:02:09,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],COMPLICATIONS include,n/a,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 12:30:27,,1323558195,7/15/2014 12:28:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],Most common,n/a,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 13:10:17,,1323573604,7/15/2014 13:10:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 13:17:05,,1323575860,7/15/2014 13:16:29,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 14:24:24,,1323596525,7/15/2014 14:24:07,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 14:31:05,,1323598537,7/15/2014 14:30:57,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 14:46:00,,1323604178,7/15/2014 14:45:35,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],Most common,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 15:06:33,,1323612761,7/15/2014 15:06:03,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Most common include ECLAMPSIA,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 16:14:27,,1323660567,7/15/2014 16:14:10,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],include,n/a,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 16:30:02,,1323677858,7/15/2014 16:29:30,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[SIDE_EFFECT],[SIDE_EFFECT],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221005,7/15/2014 16:38:04,,1323687307,7/15/2014 16:36:49,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[PART_OF],[PART_OF],include,N/A,12,78,52,87,-1,RO-disease_has_finding,901706-FS1,"Most common NON LUPUS RELATED PREGNANCY COMPLICATIONS include preeclampsia or ECLAMPSIA hypertension, the HELLP syndrome, and thrombocytopenia.",NON LUPUS RELATED PREGNANCY COMPLICATIONS,ECLAMPSIA
503221006,7/15/2014 09:59:44,,1323469501,7/15/2014 09:58:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,These seem like two different things discussed.,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 10:00:41,,1323470202,7/15/2014 10:00:28,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],secondary,na,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 10:38:32,,1323494705,7/15/2014 10:37:40,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],PHLEBITIS VARICES connection,Associated With,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 10:56:21,,1323507246,7/15/2014 10:55:34,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",elucidated the significance of in connection with,N/A,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 11:29:17,,1323529056,7/15/2014 11:28:37,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],in connection with,N/A,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 12:36:36,,1323560461,7/15/2014 12:35:51,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],PHLEBITIS VARICES in connection with post thrombotic syndroms.,N/A,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 12:36:40,,1323560484,7/15/2014 12:34:31,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],significance of in connection with,n/a,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 12:58:27,,1323569051,7/15/2014 12:57:59,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],PHLEBITIS,asds,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 13:09:15,,1323573273,7/15/2014 13:08:36,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],discussion of the terminology of and then elucidated,N/A,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 14:59:08,,1323609313,7/15/2014 14:57:55,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],secondary VARICES in connection,N/A,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 15:28:35,,1323625337,7/15/2014 15:28:05,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Different terms,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 16:02:15,,1323650753,7/15/2014 16:01:12,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],author begins with,n/a,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 16:20:06,,1323665835,7/15/2014 16:19:50,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 16:55:41,,1323706911,7/15/2014 16:55:01,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[ASSOCIATED_WITH],[ASSOCIATED_WITH],connection,NA,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221006,7/15/2014 16:58:30,,1323710309,7/15/2014 16:57:36,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[LOCATION],[LOCATION],deep veins,n/a,150,64,156,73,-1,RO-disease_has_finding,901829-FS1,The author begins with a brief discussion of the terminology of PHLEBITIS and then elucidated the significance of the deep veins and of the secondary VARICES in connection with the post thrombotic syndroms.,VARICES,PHLEBITIS
503221007,7/15/2014 10:11:39,,1323477435,7/15/2014 10:11:22,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],treated with,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 10:21:21,,1323483761,7/15/2014 10:20:43,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],OVERT CONGESTIVE HEART FAILURE was treated with FUROSEMIDE,Treats,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 11:13:36,,1323519835,7/15/2014 11:13:23,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS],[TREATS],treated,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 11:53:55,,1323543849,7/15/2014 11:52:47,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],was treated with,n/a,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 11:57:13,,1323545486,7/15/2014 11:56:54,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],treated with,n/a,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 12:40:56,,1323562037,7/15/2014 12:40:18,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],treated with,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 13:59:17,,1323589512,7/15/2014 13:58:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treated with,n/a,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 14:21:22,,1323595644,7/15/2014 14:21:09,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treated,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 14:39:23,,1323601676,7/15/2014 14:38:07,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,Na,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 14:53:44,,1323607187,7/15/2014 14:53:31,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],was treated with,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 15:26:21,,1323623769,7/15/2014 15:26:00,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treated with,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 16:12:20,,1323658862,7/15/2014 16:12:02,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treated with,n/a,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 16:29:10,,1323676860,7/15/2014 16:28:29,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treated with,N/A,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 16:52:15,,1323703325,7/15/2014 16:51:49,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[TREATS],[TREATS],treated,NA,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221007,7/15/2014 17:03:20,,1323715691,7/15/2014 17:02:13,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],treated with,n/a,25,111,54,121,1,RO-may_treat,908068-FS1,"A 51 year old woman with OVERT CONGESTIVE HEART FAILURE with pleural and pericardial effusion was treated with FUROSEMIDE and nifedipine, leading to improvement in her condition and a decrease in effusions.",OVERT CONGESTIVE HEART FAILURE,FUROSEMIDE
503221008,7/15/2014 10:08:25,,1323475741,7/15/2014 10:08:08,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],treated with,N/A,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 10:37:00,,1323493822,7/15/2014 10:36:31,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],OSTEOSARCOMA treated with CISPLATINUM,Treats,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:02:55,,1323511142,7/15/2014 11:02:35,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],were treated with,N/A,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:04:18,,1323512144,7/15/2014 11:04:07,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were treated with,n/a,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:23:58,,1323526100,7/15/2014 11:23:49,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],treated with,N/A,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:24:47,,1323526584,7/15/2014 11:24:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],were treated,N/A,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:31:58,,1323530614,7/15/2014 11:31:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],treated with,N/A,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:47:48,,1323539781,7/15/2014 11:47:16,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],were treated with,n/a,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 11:53:31,,1323543645,7/15/2014 11:53:16,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],were treated with,n/a,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 12:10:58,,1323550755,7/15/2014 12:10:47,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],were treated with,N/a,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 12:19:13,,1323553916,7/15/2014 12:18:47,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],treated,Is treated by,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 12:53:00,,1323566972,7/15/2014 12:52:45,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],OSTEOSARCOMA,dsa,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 13:37:09,,1323582719,7/15/2014 13:36:44,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[TREATS],[TREATS],treated,na,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 13:41:06,,1323584161,7/15/2014 13:40:13,clixsense,1.0,6621167,USA,"","",66.87.78.142,[SIDE_EFFECT],[SIDE_EFFECT],with,Na,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221008,7/15/2014 14:06:26,,1323591442,7/15/2014 14:05:47,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treated,n/a,19,50,30,61,1,RO-may_treat,908101-FS1,Nine patients with OSTEOSARCOMA were treated with CISPLATINUM and high dose methotrexate therapy.,OSTEOSARCOMA,CISPLATINUM
503221009,7/15/2014 09:55:52,,1323466055,7/15/2014 09:55:14,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],in suppressing,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 09:56:24,,1323466506,7/15/2014 09:55:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],suppressing the,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 10:00:27,,1323469996,7/15/2014 10:00:11,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment,na,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 10:09:56,,1323476578,7/15/2014 10:09:35,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in suppressing the,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 10:18:56,,1323482083,7/15/2014 10:18:44,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[TREATS],[TREATS],improvement,na,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 11:02:59,,1323511191,7/15/2014 11:02:41,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],suppressing,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 11:15:50,,1323521143,7/15/2014 11:15:39,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS],[TREATS],treatment,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 11:17:55,,1323522641,7/15/2014 11:17:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],induced,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 11:52:14,,1323542739,7/15/2014 11:51:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],HYDROCORTISONE in suppressing the INFLAMMATION,n/a,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 12:19:13,,1323553923,7/15/2014 12:19:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],in suppressing,N/a,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 12:28:19,,1323557389,7/15/2014 12:27:33,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],suppressing,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 12:50:00,,1323565892,7/15/2014 12:49:44,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],suppressing,n/a,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 14:01:21,,1323590089,7/15/2014 14:00:52,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],suppressing,none,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 14:08:56,,1323592108,7/15/2014 14:08:28,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],"[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",in suppressing,[DIAGNOSE_BY_TEST_OR_DRUG] [LOCATION],158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221009,7/15/2014 14:28:08,,1323597650,7/15/2014 14:28:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],symptoms,N/A,158,124,169,138,1,RO-may_treat,908222-FS1,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and HYDROCORTISONE in suppressing the INFLAMMATION,INFLAMMATION,HYDROCORTISONE
503221010,7/15/2014 10:44:36,,1323499038,7/15/2014 10:43:25,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],improved the survival in sepsis model;,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 11:54:07,,1323543950,7/15/2014 11:53:37,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],therapeutic doses of GENTAMYCIN improved the survival in clinically relevant sepsis model;,n/a,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 12:11:18,,1323550896,7/15/2014 12:11:01,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],therapeutic doses of,N/a,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 12:30:55,,1323558347,7/15/2014 12:30:29,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],therapeutic doses,n/a,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 12:35:14,,1323559909,7/15/2014 12:34:45,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],GENTAMYCIN clearly improved survival should be considered for use in clinical SEPSIS.,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 14:30:03,,1323598177,7/15/2014 14:29:47,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],clearly improved the survival,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 16:47:59,,1323698581,7/15/2014 16:46:54,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[TREATS],[TREATS],improved,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 16:50:38,,1323701564,7/15/2014 16:49:41,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],clearly improved survival,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 16:53:00,,1323704102,7/15/2014 16:52:07,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,No relation seen.,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 17:06:58,,1323719000,7/15/2014 17:06:28,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],doses of improved,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 17:09:55,,1323721341,7/15/2014 17:09:31,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[TREATS],[TREATS],improved,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 17:24:37,,1323729639,7/15/2014 17:23:41,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,[TREATS],[TREATS],clearly improved,I did not select none,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 17:31:10,,1323734890,7/15/2014 17:29:52,prodege,1.0,24118012,CAN,SK,Estevan,142.165.30.87,[TREATS],[TREATS],clearly improved the survival,n/a,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 17:39:34,,1323742709,7/15/2014 17:37:31,elite,1.0,28466071,CAN,AB,Edmonton,68.150.39.46,[OTHER],[OTHER],improved the survival,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221010,7/15/2014 17:41:27,,1323744450,7/15/2014 17:41:01,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],use clinical,N/A,285,62,290,72,1,RO-may_treat,908225-FS1,Conclusions are that (i) therapeutic doses of indomethacin or GENTAMYCIN clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical SEPSIS.,SEPSIS,GENTAMYCIN
503221011,7/15/2014 10:11:12,,1323477162,7/15/2014 10:10:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],and is a congenital degenerative disease,N/A,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 10:11:14,,1323477205,7/15/2014 10:10:13,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[NONE],[NONE],none,"Diffreent conditions, not related",28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 11:21:52,,1323524919,7/15/2014 11:21:16,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are not associated with each other.,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 11:59:47,,1323546770,7/15/2014 11:58:40,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are linked to the same chromosome but not to each other.,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 12:12:24,,1323551213,7/15/2014 12:12:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and linked,N/a,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 12:53:59,,1323567291,7/15/2014 12:53:23,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked to,N/A,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 13:35:41,,1323582230,7/15/2014 13:35:28,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],and,N/A,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 14:10:21,,1323592547,7/15/2014 14:09:47,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked to chromosome,[ASSOCIATED_WITH],28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 14:53:30,,1323607120,7/15/2014 14:52:54,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],linked to,N/A,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 15:24:02,,1323622231,7/15/2014 15:23:35,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Separate conditions,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 15:44:16,,1323637061,7/15/2014 15:44:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],FRONTOTEMPORAL DEMENTIA PARKINSONISM,n/a,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 16:43:18,,1323693322,7/15/2014 16:42:31,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and linked,n/a,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 16:50:45,,1323701651,7/15/2014 16:49:54,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[ASSOCIATED_WITH] [IS_A] [PART_OF],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",linked,NA,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 17:05:48,,1323717887,7/15/2014 17:05:15,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],linked,n/a,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221011,7/15/2014 17:09:41,,1323721173,7/15/2014 17:08:59,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and is,N/A,28,0,39,23,-1,RO-has_manifestation,906323-FS1,FRONTOTEMPORAL DEMENTIA and PARKINSONISM linked to chromosome 17 (FTDP 17) is a congenital degenerative disease of the central nervous system.,PARKINSONISM,FRONTOTEMPORAL DEMENTIA
503221012,7/15/2014 10:13:18,,1323478376,7/15/2014 10:13:01,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and serious,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 10:22:07,,1323484252,7/15/2014 10:21:33,prodege,1,22031444,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and serious,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 10:39:39,,1323495645,7/15/2014 10:38:33,neodev,1,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUTANEOUS ALLERGIC REACTIONS serious ALLERGIC VASCULITIS,Associated With,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 11:01:32,,1323510341,7/15/2014 11:01:13,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 11:40:00,,1323535244,7/15/2014 11:39:33,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and serious,n/a,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 12:24:53,,1323556135,7/15/2014 12:24:16,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUTANEOUS ALLERGIC REACTIONS ALLERGIC VASCULITIS,n/a,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 12:40:18,,1323561805,7/15/2014 12:39:51,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 13:48:10,,1323586309,7/15/2014 13:47:29,elite,1.0,28276268,USA,CA,San Rafael,98.210.32.37,[CAUSES],[CAUSES],and serious,[CAUSES],114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 13:58:04,,1323589143,7/15/2014 13:57:45,prodege,1,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],purpura,none,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 15:27:57,,1323624895,7/15/2014 15:26:50,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],Reactions ALLERGIC,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 16:01:11,,1323649860,7/15/2014 16:00:46,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 16:24:12,,1323670378,7/15/2014 16:23:41,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 16:41:37,,1323691489,7/15/2014 16:40:57,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",allergic reactions;,N/A,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 16:44:32,,1323694660,7/15/2014 16:42:00,clixsense,1,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],[NONE],sentence just sums up reactions,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221012,7/15/2014 16:45:41,,1323696108,7/15/2014 16:44:48,sendearnings,1,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,114,73,132,101,-1,RO-cause_of,900064-FS1,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; CUTANEOUS ALLERGIC REACTIONS and serious ALLERGIC VASCULITIS often with purpura of extremities and extracutaneous involvement (e.g., renal.",ALLERGIC VASCULITIS,CUTANEOUS ALLERGIC REACTIONS
503221013,7/15/2014 09:55:12,,1323465546,7/15/2014 09:54:45,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],elicited by,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 10:07:43,,1323475301,7/15/2014 10:07:17,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[MANIFESTATION],[MANIFESTATION],is manifested,na,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 11:17:24,,1323522290,7/15/2014 11:16:44,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is manifested,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 11:23:49,,1323525995,7/15/2014 11:23:14,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],elicited by,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 11:41:37,,1323536253,7/15/2014 11:41:20,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,[MANIFESTATION],[MANIFESTATION],is manifested as contact allergic eczema elicited by,n/a,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 12:01:34,,1323547470,7/15/2014 12:00:48,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],is manifested as,n/a,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 12:46:16,,1323564191,7/15/2014 12:44:20,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],elicited by,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 12:50:38,,1323566115,7/15/2014 12:50:18,clixsense,1,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ALLERGY,dsaw,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 12:53:22,,1323567044,7/15/2014 12:52:52,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],manifested,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 13:46:56,,1323585956,7/15/2014 13:46:38,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[MANIFESTATION],[MANIFESTATION],is manifested as,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 14:47:23,,1323604867,7/15/2014 14:47:07,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],manifested,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 15:03:51,,1323611534,7/15/2014 15:03:21,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[CAUSES],[CAUSES],elicited by,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 15:19:46,,1323619373,7/15/2014 15:19:28,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],elicited by,n/a,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 16:21:57,,1323667871,7/15/2014 16:21:40,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[MANIFESTATION],[MANIFESTATION],manifested,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221013,7/15/2014 16:44:40,,1323694777,7/15/2014 16:43:57,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION],[MANIFESTATION],is manifested,N/A,0,68,13,97,1,RO-cause_of,900186-FS1,NICKEL ALLERGY is manifested as contact allergic eczema elicited by DELAYED TYPE HYPERSENSITIVITY the reaction being mediated by T lymphocytes.,NICKEL ALLERGY,DELAYED TYPE HYPERSENSITIVITY
503221014,7/15/2014 09:58:19,,1323468254,7/15/2014 09:57:54,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],closely associated with,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 10:18:59,,1323482167,7/15/2014 10:18:28,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],were closely associated with,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 10:45:43,,1323499843,7/15/2014 10:44:37,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[ASSOCIATED_WITH],[ASSOCIATED_WITH],closely associated with,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 10:59:35,,1323509173,7/15/2014 10:58:51,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],ASPHYXIATION ASPHYXIA,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 11:24:31,,1323526410,7/15/2014 11:23:39,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",associated with,not applicable,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 11:36:34,,1323533286,7/15/2014 11:36:06,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 11:51:20,,1323542031,7/15/2014 11:51:00,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],suicides involving ASPHYXIATION were closely associated with ASPHYXIA,n/a,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 12:15:01,,1323552364,7/15/2014 12:14:21,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ASPHYXIATION ASPHYXIA,n/a,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 12:37:55,,1323560944,7/15/2014 12:36:41,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,n/a,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 12:56:56,,1323568363,7/15/2014 12:56:20,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ASPHYXIA,asd,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 13:34:00,,1323581697,7/15/2014 13:33:48,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were closely associated with,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 14:31:15,,1323598577,7/15/2014 14:31:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],that,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 15:38:03,,1323632296,7/15/2014 15:37:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[CONTRAINDICATES] [MANIFESTATION],"[MANIFESTATION]
[CONTRAINDICATES]",ASPHYXIATION ASPHYXIA,n/a,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 16:05:06,,1323653090,7/15/2014 16:04:45,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],closely associated with,n/a,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221014,7/15/2014 16:25:53,,1323672344,7/15/2014 16:24:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,100,100,111,108,-1,RO-cause_of,900221-FS1,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving ASPHYXIATION were closely associated with ASPHYXIA at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",ASPHYXIATION,ASPHYXIA
503221015,7/15/2014 09:52:58,,1323463959,7/15/2014 09:52:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],DEPENDENCE USE,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 11:03:35,,1323511641,7/15/2014 11:03:15,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],users,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 11:13:59,,1323520102,7/15/2014 11:13:38,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],differences,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 12:47:49,,1323564893,7/15/2014 12:46:17,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],detected among users,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 12:53:18,,1323567029,7/15/2014 12:53:03,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],HEROIN DEPENDENCE were detected among HEROIN USE,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 13:18:11,,1323576286,7/15/2014 13:17:35,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SIDE_EFFECT],[SIDE_EFFECT],were detected among users,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 13:27:56,,1323579639,7/15/2014 13:27:26,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",detected among,na,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 14:01:01,,1323590030,7/15/2014 14:00:25,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],users with,n/a,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 14:25:55,,1323596855,7/15/2014 14:25:17,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],detected,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 14:31:08,,1323598548,7/15/2014 14:30:48,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],detected among users,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 14:43:10,,1323603124,7/15/2014 14:42:29,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],among users,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 15:21:47,,1323620690,7/15/2014 15:21:20,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],detected among users,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 16:28:28,,1323675781,7/15/2014 16:28:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were detected,N/A,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 16:49:54,,1323700765,7/15/2014 16:48:56,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",detected,NA,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221015,7/15/2014 17:05:14,,1323717311,7/15/2014 17:04:20,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],of,n/a,108,40,117,57,1,RO-has_causative_agent,903579-FS1,"No major differences in the severity of HEROIN DEPENDENCE were detected among users with 5 or more years of HEROIN USE (long term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",HEROIN USE,HEROIN DEPENDENCE
503221016,7/15/2014 10:10:24,,1323476729,7/15/2014 10:09:53,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,na,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 10:17:04,,1323480848,7/15/2014 10:16:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[MANIFESTATION],[MANIFESTATION],aggravation is associated,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 10:31:24,,1323490165,7/15/2014 10:30:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GRAVES' DISEASE associated THYROTOXICOSIS.,Associated With,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 11:08:58,,1323516468,7/15/2014 11:08:32,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,n/a,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 11:23:13,,1323525648,7/15/2014 11:22:53,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],associated with,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 11:31:00,,1323529999,7/15/2014 11:30:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 11:48:31,,1323540112,7/15/2014 11:48:06,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Thyrotoxicosis in GRAVES' DISEASE is often aggravated,n/a,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 12:51:16,,1323566329,7/15/2014 12:50:59,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[LOCATION],[LOCATION],Thyrotoxicosis DISEASE,dsaw,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 12:53:35,,1323567169,7/15/2014 12:53:19,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GRAVES' DISEASE is associated with THYROTOXICOSIS.,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 13:07:16,,1323572537,7/15/2014 13:07:01,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is associated with,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 14:04:11,,1323590804,7/15/2014 14:03:35,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with postpartum relapse,[ASSOCIATED_WITH],18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 14:28:44,,1323597855,7/15/2014 14:28:35,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],in,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 15:07:03,,1323612968,7/15/2014 15:06:34,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],Thyrotoxicosis in GRAVES' DISEASE,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 15:20:45,,1323619973,7/15/2014 15:20:04,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],in,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221016,7/15/2014 16:19:05,,1323664752,7/15/2014 16:18:47,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,N/A,18,135,32,149,-1,RO-cause_of,900105-FS1,Thyrotoxicosis in GRAVES' DISEASE is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of THYROTOXICOSIS.,GRAVES' DISEASE,THYROTOXICOSIS
503221017,7/15/2014 10:10:55,,1323477053,7/15/2014 10:10:25,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],can rapidly progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 10:34:18,,1323491995,7/15/2014 10:33:12,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEIZURES rapidly progress STATUS EPILEPTICUS,Associated With,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 10:49:25,,1323502701,7/15/2014 10:48:36,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [IS_A] [OTHER],"[CAUSES]
[IS_A]
[OTHER]",can rapidly progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 11:17:51,,1323522601,7/15/2014 11:17:23,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],can progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 11:30:02,,1323529428,7/15/2014 11:29:49,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],rapidly progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 11:55:53,,1323544720,7/15/2014 11:55:32,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],rapidly progress,n/a,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 12:18:01,,1323553449,7/15/2014 12:17:11,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],SEIZURES STATUS EPILEPTICUS,n/a,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 12:37:30,,1323560812,7/15/2014 12:36:28,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],can rapidly progress,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 13:08:35,,1323572974,7/15/2014 13:08:09,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],can rapidly progress,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 13:11:17,,1323573931,7/15/2014 13:11:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 13:28:30,,1323579810,7/15/2014 13:28:17,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[MANIFESTATION],[MANIFESTATION],can rapidly progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 14:30:13,,1323598231,7/15/2014 14:30:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],mortality,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 14:44:34,,1323603629,7/15/2014 14:43:46,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[PART_OF],[PART_OF],rapidly progress,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 15:10:01,,1323614211,7/15/2014 15:09:31,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],progress to,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221017,7/15/2014 15:18:16,,1323618543,7/15/2014 15:17:41,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[MANIFESTATION],[MANIFESTATION],rapidly progress,N/A,0,33,7,51,-1,RO-has_definitional_manifestation,904791-FS1,"SEIZURES can rapidly progress to STATUS EPILEPTICUS contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",SEIZURES,STATUS EPILEPTICUS
503221018,7/15/2014 09:55:22,,1323465628,7/15/2014 09:54:32,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,The second term is an organisation that makes classifications.,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 10:35:55,,1323493084,7/15/2014 10:34:20,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",MIGRAINE VARIANT OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,manifestation/associated with,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 10:52:46,,1323504950,7/15/2014 10:51:56,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,One is a symptom and the other is an organization.,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 11:15:23,,1323520878,7/15/2014 11:14:48,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],included,N/A,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 11:24:42,,1323526504,7/15/2014 11:24:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],HEADACHE SOCIETY,N/A,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 11:34:11,,1323531919,7/15/2014 11:33:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[OTHER],[OTHER],was included,N/A,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 11:46:39,,1323539153,7/15/2014 11:45:35,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE VARIANT Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,n/a,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 11:58:39,,1323546227,7/15/2014 11:58:00,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],in the first Headache Classification OF,n/a,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 12:19:22,,1323554032,7/15/2014 12:18:49,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MIGRAINE VARIANT OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,n/a,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 12:19:42,,1323554137,7/15/2014 12:18:06,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[OTHER],[OTHER],in the first Headache Classification,"included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.  

It was classified by an orginzation.",87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 12:46:03,,1323564067,7/15/2014 12:45:24,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],N/A,The society is a group of people who names headaches,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 12:48:11,,1323565124,7/15/2014 12:47:08,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Classification,N/A,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 12:54:32,,1323567490,7/15/2014 12:54:21,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],included,asd,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 13:08:57,,1323573137,7/15/2014 13:08:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,The Headache Society is a group that studies headaches. Migraine variant has no direct link with this term.,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221018,7/15/2014 13:37:54,,1323582954,7/15/2014 13:37:18,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],Classification OF THE,na,87,33,131,49,-1,RO-has_definitional_manifestation,904551-FS1,This condition was included as a MIGRAINE VARIANT in the first Headache Classification OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988.,OF THE INTERNATIONAL HEADACHE SOCIETY IN 1988,MIGRAINE VARIANT
503221019,7/15/2014 10:02:52,,1323471930,7/15/2014 10:02:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],excluded.,na,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 10:12:06,,1323477692,7/15/2014 10:11:44,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other neuropathies than,na,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 10:43:19,,1323498101,7/15/2014 10:42:13,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],other neuropathies than DIABETIC NEUROPATHY can be excluded.,N/A,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 11:10:57,,1323517987,7/15/2014 11:10:41,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIABETES DIABETIC,N/A,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 11:36:04,,1323533057,7/15/2014 11:35:40,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed as,N/A,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 12:11:57,,1323551059,7/15/2014 12:11:39,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],other neuropathies,N/a,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 12:45:05,,1323563701,7/15/2014 12:44:32,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],other neuropathies,both cause neuropathy,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 12:52:07,,1323566664,7/15/2014 12:51:52,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],condition includes: DIABETES and DIABETIC NEUROPATHY,N/A,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 14:04:41,,1323590951,7/15/2014 14:04:05,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CONTRAINDICATES],[CONTRAINDICATES],excluded.,none,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 16:21:38,,1323667498,7/15/2014 16:21:09,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],can be excluded.,N/A,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 16:46:43,,1323697286,7/15/2014 16:45:37,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[ASSOCIATED_WITH] [SYMPTOM] [CAUSES] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",diagnosed,NA,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 16:53:30,,1323704579,7/15/2014 16:53:02,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],other neuropathies,n/a,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 16:59:42,,1323711868,7/15/2014 16:58:15,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],includes:,n/a,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 16:59:56,,1323712139,7/15/2014 16:59:06,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms were to be found.,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221019,7/15/2014 17:06:33,,1323718556,7/15/2014 17:05:52,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],and,N/A,95,54,113,62,-1,RO-cause_of,900076-FS1,The prerequisite condition includes: (1) diagnosed as DIABETES and (2) other neuropathies than DIABETIC NEUROPATHY can be excluded.,DIABETIC NEUROPATHY,DIABETES
503221020,7/15/2014 10:04:34,,1323473285,7/15/2014 10:03:58,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],the role of in the pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 10:08:15,,1323475638,7/15/2014 10:07:45,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[CAUSES],[CAUSES],pathogenesis of,na,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 10:10:41,,1323476920,7/15/2014 10:10:16,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],pathogenesis,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 10:43:24,,1323498195,7/15/2014 10:42:48,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],in pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 10:58:49,,1323508704,7/15/2014 10:58:07,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],in the pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 11:34:32,,1323532115,7/15/2014 11:34:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],in the pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 11:59:40,,1323546700,7/15/2014 11:59:16,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[MANIFESTATION],[MANIFESTATION],in the pathogenesis of,n/a,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 13:04:12,,1323571393,7/15/2014 13:03:46,clixsense,1.0,6621167,USA,"","",66.87.78.142,[SIDE_EFFECT],[SIDE_EFFECT],in,Na,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 13:10:33,,1323573693,7/15/2014 13:10:17,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],in the pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 13:18:48,,1323576501,7/15/2014 13:18:12,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],in the pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 15:18:04,,1323618435,7/15/2014 15:17:18,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[CAUSES],[CAUSES],pathogenesis of,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 15:53:48,,1323644182,7/15/2014 15:53:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],pathogenesis,n\a,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 16:03:34,,1323651790,7/15/2014 16:03:03,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],pathogenesis,n/a,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 16:13:25,,1323659743,7/15/2014 16:12:44,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the,N/A,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221020,7/15/2014 16:47:23,,1323698026,7/15/2014 16:46:27,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,No relation,30,88,63,123,-1,RO-has_causative_agent,903982-FS1,Current models of the role of HUMAN IMMUNODEFICIENCY VIRUS (HIV) in the pathogenesis of ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS) are inadequate and inconsistent with the literature.,HUMAN IMMUNODEFICIENCY VIRUS (HIV),ACQUIRED IMMUNE DEFICIENCY SYNDROME
503221021,7/15/2014 10:11:05,,1323477109,7/15/2014 10:10:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],asystole,N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 10:15:43,,1323479944,7/15/2014 10:15:12,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[TREATS],[TREATS],commonly used medications,na,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 10:22:53,,1323484723,7/15/2014 10:22:09,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],"anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow),",N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 11:10:29,,1323517623,7/15/2014 11:10:01,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],if the is asystole,n/a,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 11:20:48,,1323524326,7/15/2014 11:19:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],if the ARREST ARRHYTHMIA is asystole,N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 11:36:27,,1323533203,7/15/2014 11:36:03,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AGENTS (ATROPINE ARREST ARRHYTHMIA,n/a,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 11:50:39,,1323541531,7/15/2014 11:50:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA,n/a,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 12:02:08,,1323547665,7/15/2014 11:59:48,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[OTHER],[OTHER],if the is asystole,n/a,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 12:15:20,,1323552474,7/15/2014 12:15:00,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],commonly used medications in,N/a,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 12:28:58,,1323557634,7/15/2014 12:28:12,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AGENTS (ATROPINE ARREST ARRHYTHMIA,n/a,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 12:50:28,,1323566016,7/15/2014 12:50:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[IS_A],[IS_A],"anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow),",N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 14:19:27,,1323595021,7/15/2014 14:18:58,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],if the,[DIAGNOSE_BY_TEST_OR_DRUG],248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 14:27:28,,1323597441,7/15/2014 14:27:21,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],problems,N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 15:26:49,,1323624129,7/15/2014 15:25:35,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],commonly used medications,N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221021,7/15/2014 15:31:46,,1323627746,7/15/2014 15:31:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],commonly used medications,N/A,248,224,264,240,1,RO-may_treat,907823-FS1,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic AGENTS (ATROPINE if the ARREST ARRHYTHMIA is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",ARREST ARRHYTHMIA,AGENTS (ATROPINE
503221022,7/15/2014 09:59:34,,1323469389,7/15/2014 09:59:20,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],differential diagnosis,na,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 10:19:39,,1323482672,7/15/2014 10:18:51,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PTLD differential diagnosis LYMPHADENOPATHY,diagnosed by test or drug,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 11:08:30,,1323516005,7/15/2014 11:08:04,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],considering differential diagnosis,n/a,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 11:32:32,,1323530890,7/15/2014 11:32:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in the differential diagnosis of,N/A,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 11:48:53,,1323540314,7/15/2014 11:48:32,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY,n/a,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 11:50:16,,1323541254,7/15/2014 11:48:11,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],PTLD LYMPHADENOPATHY,n/a,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 12:12:38,,1323551411,7/15/2014 12:12:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in the differential diagnosis,N/a,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 12:39:35,,1323561639,7/15/2014 12:38:26,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[ASSOCIATED_WITH],[ASSOCIATED_WITH],importance in diagnosis,N/A,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 12:49:37,,1323565800,7/15/2014 12:49:20,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],considering,dsasd,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 13:06:05,,1323572064,7/15/2014 13:05:47,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in the differential diagnosis,N/A,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 14:28:12,,1323597689,7/15/2014 14:26:40,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 15:17:17,,1323617979,7/15/2014 15:17:01,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 16:10:49,,1323657570,7/15/2014 16:10:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 16:19:23,,1323664984,7/15/2014 16:19:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221022,7/15/2014 16:39:45,,1323689356,7/15/2014 16:39:14,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,90,52,104,56,1,RO-disease_may_have_finding,902895-FS1,These cases highlight the importance of considering PTLD in the differential diagnosis of LYMPHADENOPATHY and fever post ASCT.,LYMPHADENOPATHY,PTLD
503221023,7/15/2014 10:02:03,,1323471343,7/15/2014 10:01:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],seldom present,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 10:07:41,,1323475297,7/15/2014 10:07:14,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],present,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 11:13:21,,1323519682,7/15/2014 11:12:10,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seldom present,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 11:24:12,,1323526244,7/15/2014 11:23:59,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],seldom present with,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 11:27:36,,1323528091,7/15/2014 11:27:07,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",seldom present,not applicable,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 11:30:04,,1323529452,7/15/2014 11:29:23,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],present with,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 11:55:51,,1323544711,7/15/2014 11:55:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,n/a,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 12:34:41,,1323559658,7/15/2014 12:33:43,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[CONTRAINDICATES],[CONTRAINDICATES],seldom present with,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 12:39:34,,1323561638,7/15/2014 12:39:13,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 12:48:58,,1323565513,7/15/2014 12:48:13,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],seldom present with,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 13:34:23,,1323581827,7/15/2014 13:34:06,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],seldom present with,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 13:36:11,,1323582440,7/15/2014 13:35:39,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",present with,na,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 14:42:28,,1323602917,7/15/2014 14:42:16,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],seldom present,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 15:14:58,,1323616782,7/15/2014 15:14:33,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[OTHER],[OTHER],seldom present,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221023,7/15/2014 15:24:59,,1323622870,7/15/2014 15:24:35,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],seldom present with,N/A,40,0,49,19,1,RO-disease_may_have_finding,902535-FS1,CENTRAL NEUROCYTOMA seldom present with HEMORRHAGE,HEMORRHAGE,CENTRAL NEUROCYTOMA
503221024,7/15/2014 10:02:00,,1323471241,7/15/2014 10:01:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[PREVENTS],[PREVENTS],prevent,na,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 10:07:12,,1323475063,7/15/2014 10:06:13,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[CONTRAINDICATES],[CONTRAINDICATES],complicating the treatment of,N/A,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 11:14:04,,1323520129,7/15/2014 11:13:32,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],complicating the treatment,n/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 11:21:03,,1323524459,7/15/2014 11:20:44,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS],[TREATS],treated with,N/A,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 11:30:15,,1323529609,7/15/2014 11:29:15,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[SIDE_EFFECT],[SIDE_EFFECT],Care must be taken to prevent,n/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 13:03:45,,1323571242,7/15/2014 13:02:53,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],into,Na,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 13:52:32,,1323587446,7/15/2014 13:52:17,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],complicating the treatment of,N/A,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 13:53:10,,1323587653,7/15/2014 13:50:50,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SIDE_EFFECT],[SIDE_EFFECT],complicating the treatment,n/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 14:29:33,,1323598034,7/15/2014 14:28:52,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SIDE_EFFECT],[SIDE_EFFECT],complicating the treatment,N/A,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 14:46:36,,1323604499,7/15/2014 14:46:01,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],universally treated with,N/A,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 15:29:29,,1323626067,7/15/2014 15:29:01,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],complicating the treatment,N/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 15:43:37,,1323636467,7/15/2014 15:43:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],INTRAVASCULAR COAGULATION APL,n/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 16:10:10,,1323657065,7/15/2014 16:09:22,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],complicating the treatment of APL,n/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 16:34:37,,1323683195,7/15/2014 16:33:32,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",treated prevent treatment,N/A,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221024,7/15/2014 16:56:21,,1323707740,7/15/2014 16:55:12,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",complicating treatment,n/a,236,297,265,300,1,RO-disease_may_have_finding,902931-FS1,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all trans retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated INTRAVASCULAR COAGULATION (DIC complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",INTRAVASCULAR COAGULATION (DIC,APL
503221025,7/15/2014 09:54:56,,1323465345,7/15/2014 09:54:39,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],well,na,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 10:08:07,,1323475589,7/15/2014 10:07:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],NON EPILEPTIC as well as SEIZURE PRONE,N/A,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 10:16:26,,1323480286,7/15/2014 10:16:04,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 10:55:27,,1323506769,7/15/2014 10:54:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],as well as,opposites,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 11:17:32,,1323522372,7/15/2014 11:17:11,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],as well as,n/a,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 11:35:05,,1323532475,7/15/2014 11:33:54,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NON EPILEPTIC SEIZURE PRONE RODENTS,n/a,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 12:09:19,,1323550135,7/15/2014 12:08:31,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,they are both the test groups,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 12:30:22,,1323558167,7/15/2014 12:29:43,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NON EPILEPTIC SEIZURE PRONE RODENTS,n/a,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 12:50:55,,1323566209,7/15/2014 12:50:42,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],NON,dsaw,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 13:11:28,,1323573987,7/15/2014 13:11:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 13:54:04,,1323587894,7/15/2014 13:53:31,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Both,none,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 14:18:58,,1323594930,7/15/2014 14:18:33,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,N/A,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 14:21:27,,1323595677,7/15/2014 14:21:02,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as well as,[ASSOCIATED_WITH],38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 14:27:20,,1323597369,7/15/2014 14:27:11,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],RODENTS,N/A,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221025,7/15/2014 15:05:10,,1323612088,7/15/2014 15:03:52,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,The two are direct opposites of one another and as such have no relation to each other.,38,13,58,26,-1,RO-has_definitional_manifestation,904835-FS1,"Both normal, NON EPILEPTIC as well as SEIZURE PRONE RODENTS exhibit a spectrum of anxiogenic like behaviors in response to stressor exposure.",SEIZURE PRONE RODENTS,NON EPILEPTIC
503221026,7/15/2014 10:02:33,,1323471650,7/15/2014 10:02:22,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],complication,na,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 10:13:36,,1323478543,7/15/2014 10:13:19,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],is the most frequent complication of,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 10:40:35,,1323496250,7/15/2014 10:39:27,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[MANIFESTATION] [CAUSES],"[CAUSES]
[MANIFESTATION]",most frequent complication of,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 11:16:46,,1323521719,7/15/2014 11:16:22,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[SYMPTOM],[SYMPTOM],most frequent complication,n/a,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 11:20:28,,1323524175,7/15/2014 11:19:28,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",most frequent complication,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 12:39:50,,1323561692,7/15/2014 12:39:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],DIABETIC NEUROPATHY is complication of DIABETES,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 14:49:40,,1323605699,7/15/2014 14:48:59,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],frequent complication,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 16:54:31,,1323705684,7/15/2014 16:53:59,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[MANIFESTATION],[MANIFESTATION],of,n/a,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:09:12,,1323720850,7/15/2014 17:08:58,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],complication,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:10:19,,1323721642,7/15/2014 17:09:45,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[MANIFESTATION],[MANIFESTATION],complication,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:13:10,,1323723760,7/15/2014 17:12:21,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",frequent complication cause,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:13:57,,1323724176,7/15/2014 17:13:25,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM] [CAUSES] [SIDE_EFFECT],"[CAUSES]
[SYMPTOM]
[SIDE_EFFECT]",frequent complication,n/a,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:25:12,,1323730095,7/15/2014 17:24:39,clixsense,1.0,24896327,GBR,V2,Glasgow,94.2.231.4,[MANIFESTATION],[MANIFESTATION],the most frequent complication,I did not,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:29:52,,1323733793,7/15/2014 17:26:54,prodege,1,24118012,CAN,SK,Estevan,142.165.30.87,[SYMPTOM],[SYMPTOM],most frequent complication,n/a,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221026,7/15/2014 17:40:16,,1323743399,7/15/2014 17:39:35,elite,1,28466071,CAN,AB,Edmonton,68.150.39.46,[SYMPTOM],[SYMPTOM],complication,N/A,0,57,18,65,1,RO-cause_of,900359-FS1,DIABETIC NEUROPATHY is the most frequent complication of DIABETES and the leading cause of polyneuropathy in the Western world.,DIABETIC NEUROPATHY,DIABETES
503221027,7/15/2014 10:02:57,,1323472031,7/15/2014 10:02:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION],[MANIFESTATION],characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 10:09:31,,1323476367,7/15/2014 10:09:12,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 11:02:40,,1323510976,7/15/2014 11:02:26,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],characterised,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 11:30:20,,1323529650,7/15/2014 11:30:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 11:30:34,,1323529789,7/15/2014 11:30:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 12:16:23,,1323552820,7/15/2014 12:16:11,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],characterised by,N/a,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 13:00:23,,1323570042,7/15/2014 12:59:39,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[PART_OF],[PART_OF],characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 13:21:32,,1323577480,7/15/2014 13:21:00,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],is rare myeloproliferative disease characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 13:29:00,,1323580032,7/15/2014 13:28:29,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],raised,na,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 13:31:44,,1323580810,7/15/2014 13:31:28,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[MANIFESTATION],[MANIFESTATION],characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 14:06:56,,1323591541,7/15/2014 14:06:15,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],characterised,none,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 14:26:55,,1323597204,7/15/2014 14:26:43,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],characterised,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 14:45:35,,1323604066,7/15/2014 14:44:35,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],characterised by,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 15:30:41,,1323626963,7/15/2014 15:30:25,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],characterised,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221027,7/15/2014 16:29:28,,1323677323,7/15/2014 16:29:12,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterised,N/A,85,0,96,30,1,RO-disease_has_finding,901967-FS1,"CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease characterised by SPLENOMEGALY sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA
503221028,7/15/2014 10:00:10,,1323469774,7/15/2014 09:59:49,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,na,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 10:08:21,,1323475712,7/15/2014 10:07:21,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[SYMPTOM],[SYMPTOM],OSTEOID OSTEOMA history PAIN,symptom,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 10:11:23,,1323477254,7/15/2014 10:10:56,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[PREVENTS],[PREVENTS],diagnosis of a history of relief of,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 11:11:15,,1323518278,7/15/2014 11:10:58,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],history of,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 11:14:20,,1323520262,7/15/2014 11:14:00,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[TREATS],[TREATS],relief,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 11:23:08,,1323525605,7/15/2014 11:22:27,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]",diagnosis history of relief,not applicable,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 11:30:42,,1323529864,7/15/2014 11:30:21,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],relief of,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 11:47:30,,1323539628,7/15/2014 11:46:44,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin,n/a,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 11:49:43,,1323540824,7/15/2014 11:47:49,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[SYMPTOM],[SYMPTOM],a history of relief of,n/a,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 12:33:13,,1323559177,7/15/2014 12:32:35,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],OSTEOID OSTEOMA relief PAIN,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 12:44:19,,1323563370,7/15/2014 12:43:32,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[SYMPTOM],[SYMPTOM],a history of,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 12:49:17,,1323565649,7/15/2014 12:49:00,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],OSTEOID,dsada,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 12:51:35,,1323566448,7/15/2014 12:51:17,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of OSTEOID OSTEOMA a history of relief of PAIN is important.,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 13:07:32,,1323572609,7/15/2014 13:07:17,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],relief of,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221028,7/15/2014 13:53:03,,1323587611,7/15/2014 13:52:42,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],history of relief of,N/A,59,20,62,35,1,RO-disease_has_finding,901848-FS1,In the diagnosis of OSTEOID OSTEOMA a history of relief of PAIN with aspirin is important.,PAIN,OSTEOID OSTEOMA
503221029,7/15/2014 10:01:27,,1323470868,7/15/2014 10:01:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],complication,na,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 10:48:34,,1323501964,7/15/2014 10:47:46,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",as a complication of,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 11:12:09,,1323518887,7/15/2014 11:11:38,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],complication,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 11:20:45,,1323524312,7/15/2014 11:19:54,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],with pneumaturia as a complication,not applicable,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 11:29:37,,1323529168,7/15/2014 11:29:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],as a complication of,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 11:36:34,,1323533271,7/15/2014 11:35:58,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[MANIFESTATION],[MANIFESTATION],as a complication of,n/a,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 11:52:34,,1323543019,7/15/2014 11:52:16,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],pneumaturia due to SIGMOIDO VESICAL FISTULA complication of CROHN'S DISEASE,n/a,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 11:58:11,,1323545965,7/15/2014 11:57:52,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],as a complication of,n/a,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 12:30:02,,1323558024,7/15/2014 12:29:15,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],complication of,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 12:32:27,,1323558844,7/15/2014 12:31:52,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],SIGMOIDO VESICAL FISTULA CROHN'S DISEASE,n/a,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 12:36:59,,1323560625,7/15/2014 12:36:38,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 12:44:45,,1323563541,7/15/2014 12:43:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as a complication of,n/a,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 12:54:45,,1323567519,7/15/2014 12:54:01,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],complication,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 13:12:36,,1323574370,7/15/2014 13:12:22,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],as a complication of,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221029,7/15/2014 13:28:57,,1323580022,7/15/2014 13:28:31,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[MANIFESTATION],[MANIFESTATION],as a complication of,N/A,67,113,90,128,1,RO-has_manifestation,906063-FS1,We experienced a case of a 16 year old boy with pneumaturia due to SIGMOIDO VESICAL FISTULA as a complication of CROHN'S DISEASE,SIGMOIDO VESICAL FISTULA,CROHN'S DISEASE
503221030,7/15/2014 10:11:43,,1323477498,7/15/2014 10:11:18,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation of,na,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 11:08:49,,1323516289,7/15/2014 11:08:35,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],effect of,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 12:14:59,,1323552379,7/15/2014 12:14:44,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],evaluation of the effect of activated,N/a,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 12:49:37,,1323565799,7/15/2014 12:49:10,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],effect of activated CHARCOAL ACETAMINOPHEN OVERDOSE,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 14:21:39,,1323595736,7/15/2014 14:21:23,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],evaluation,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 14:30:56,,1323598500,7/15/2014 14:30:48,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],before,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 14:42:15,,1323602791,7/15/2014 14:41:39,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],effect,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 14:59:54,,1323609561,7/15/2014 14:59:09,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],effect of,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 15:43:22,,1323636247,7/15/2014 15:43:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHARCOAL ACETAMINOPHEN OVERDOSE,n/a,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 16:49:37,,1323700444,7/15/2014 16:48:00,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],[NONE],no relation is stated,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 16:55:00,,1323706187,7/15/2014 16:54:19,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation,NA,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 16:59:03,,1323711008,7/15/2014 16:58:03,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms found.,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 17:05:51,,1323717956,7/15/2014 17:04:54,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[CAUSES],[CAUSES],activated,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 17:07:09,,1323719145,7/15/2014 17:06:26,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[NONE],[NONE],n/a,No relation can be found.,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221030,7/15/2014 17:11:06,,1323722223,7/15/2014 17:10:23,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],effect,N/A,93,52,114,60,1,RO-may_treat,907670-FS1,A prospective evaluation of the effect of activated CHARCOAL before oral N acetylcysteine in ACETAMINOPHEN OVERDOSE,ACETAMINOPHEN OVERDOSE,CHARCOAL
503221031,7/15/2014 10:12:58,,1323478168,7/15/2014 10:12:28,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],at risk for and,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 10:13:18,,1323478372,7/15/2014 10:12:45,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],and potential,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 10:17:06,,1323480872,7/15/2014 10:16:04,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[CAUSES],[CAUSES],at risk,na,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 10:51:30,,1323504173,7/15/2014 10:50:51,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],at risk for potential,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 11:22:23,,1323525138,7/15/2014 11:20:57,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],demonstrated,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 12:17:20,,1323553218,7/15/2014 12:17:03,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],are at risk,N/a,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 12:27:24,,1323557124,7/15/2014 12:26:30,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MERCURY EXPOSURE MERCURY TOXICITY.,n/a,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 12:48:27,,1323565251,7/15/2014 12:48:10,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MERCURY EXPOSURE and MERCURY TOXICITY.,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 12:48:50,,1323565429,7/15/2014 12:47:53,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 13:28:27,,1323579797,7/15/2014 13:27:57,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT],[SIDE_EFFECT],effects,na,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 13:29:19,,1323580115,7/15/2014 13:28:58,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[PART_OF],[PART_OF],and,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 13:56:41,,1323588687,7/15/2014 13:56:22,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],risk,none,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 14:22:28,,1323595932,7/15/2014 14:22:13,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],risk,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 14:38:06,,1323601196,7/15/2014 14:36:10,clixsense,1.0,6621167,USA,"","",66.87.78.142,[SIDE_EFFECT],[SIDE_EFFECT],and,Na,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221031,7/15/2014 15:16:05,,1323617362,7/15/2014 15:15:35,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],risk,N/A,160,129,175,145,-1,RO-has_causative_agent,903593-FS1,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for MERCURY EXPOSURE and potential MERCURY TOXICITY.",MERCURY TOXICITY,MERCURY EXPOSURE
503221032,7/15/2014 10:20:42,,1323483321,7/15/2014 10:19:40,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BORRELIA BURGDORFERI region LYME DISEASE,associated with,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 11:11:02,,1323518044,7/15/2014 11:10:31,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],in three categories,n/a,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 11:18:45,,1323523153,7/15/2014 11:17:47,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[ASSOCIATED_WITH],[ASSOCIATED_WITH],from the,not applicable,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 11:31:27,,1323530283,7/15/2014 11:31:01,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],antibodies against,N/A,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 12:13:29,,1323551697,7/15/2014 12:12:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],prevalence of antibodies against,N/a,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 12:22:04,,1323555092,7/15/2014 12:20:51,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],region of LYME DISEASE,n/a,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 12:53:17,,1323567026,7/15/2014 12:53:04,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CONTRAINDICATES],[CONTRAINDICATES],northeast,dsa,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 13:20:59,,1323577276,7/15/2014 13:20:28,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],from the endemic region of,N/A,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 13:27:37,,1323579520,7/15/2014 13:27:16,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],subjects from the endemic region,N/A,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 13:55:52,,1323588445,7/15/2014 13:54:11,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],of,n/a,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 14:25:01,,1323596676,7/15/2014 14:24:28,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],in three categories of,[DIAGNOSE_BY_TEST_OR_DRUG],65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 14:52:53,,1323606865,7/15/2014 14:52:22,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study of the prevalence,N/A,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 15:17:00,,1323617826,7/15/2014 15:15:32,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[NONE],[NONE],N/A,"There is nothing in the sentence that states there is a relationship between the two, only that a potential relationship has been studied. Without the results, a relationship cannot be firmly stated.",65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 16:26:13,,1323672633,7/15/2014 16:25:53,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],endemic region,N/A,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221032,7/15/2014 16:33:31,,1323681887,7/15/2014 16:32:58,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study,N/A,65,145,84,157,-1,RO-has_causative_agent,903632-FS1,The results of the study of the prevalence of antibodies against BORRELIA BURGDORFERI in three categories of subjects from the endemic region of LYME DISEASE in the northeast Croatia are reported.,BORRELIA BURGDORFERI,LYME DISEASE
503221033,7/15/2014 10:08:27,,1323475748,7/15/2014 10:08:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,N/A,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 10:14:10,,1323478929,7/15/2014 10:13:30,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],could be diagnosed,N/A,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 10:18:23,,1323481644,7/15/2014 10:17:51,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[SYMPTOM],[SYMPTOM],could be diagnosed,na,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 10:20:09,,1323482911,7/15/2014 10:19:43,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],could be diagnosed pre operatively,N/A,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 11:27:05,,1323527796,7/15/2014 11:26:22,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,not applicable,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 11:31:44,,1323530450,7/15/2014 11:30:44,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed pre operatively,N/A,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 11:42:12,,1323536678,7/15/2014 11:40:01,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],be diagnosed pre operatively in 34 of 46 (76%) of patients with,n/a,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 11:53:36,,1323543684,7/15/2014 11:52:59,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],revealed that bladder tumours could be diagnosed pre operatively in patients with gross HAEMATURIA,n/a,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 12:22:22,,1323555220,7/15/2014 12:21:40,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CARCINOMA OF THE BLADDER HAEMATURIA,n/a,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 12:32:38,,1323558932,7/15/2014 12:32:05,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CARCINOMA OF THE BLADDER revealed that HAEMATURIA,N/A,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 13:23:37,,1323578103,7/15/2014 13:23:00,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],could be diagnosed with gross,N/A,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 13:32:25,,1323581022,7/15/2014 13:31:04,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,na,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 13:42:34,,1323584580,7/15/2014 13:42:00,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,Na,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 13:52:52,,1323587564,7/15/2014 13:52:17,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosed,none,222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221033,7/15/2014 14:09:38,,1323592318,7/15/2014 14:08:58,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],revealed that,[DIAGNOSE_BY_TEST_OR_DRUG],222,91,231,115,1,RO-disease_may_have_finding,902786-FS1,A retrospective review of 64 patients with haematuria and subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively in 34 of 46 (76%) of patients with gross HAEMATURIA and 12 of of 18 (67%) of those with microhaematuria.,HAEMATURIA,CARCINOMA OF THE BLADDER
503221034,7/15/2014 10:08:43,,1323475900,7/15/2014 10:07:42,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,The same thing,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 10:30:33,,1323489481,7/15/2014 10:29:34,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],CULTURE PROVEN SEPSIS CULTURE NEGATIVE SEPSIS,Is A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 10:52:28,,1323504799,7/15/2014 10:50:30,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[NONE],[NONE],N/A,"Cannot find a specific relation between them, within the options given",98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 10:56:30,,1323507323,7/15/2014 10:56:00,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEPSIS SEPSIS,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 11:06:38,,1323514303,7/15/2014 11:06:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CULTURE SEPSIS CULTURE SEPSIS,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 11:07:45,,1323515335,7/15/2014 11:07:04,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There are no words that indicate a relation between the two.,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 11:44:57,,1323538137,7/15/2014 11:44:13,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,none of the relations given fit this sentence,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 12:53:01,,1323566973,7/15/2014 12:52:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],CULTURE PROVEN SEPSIS CULTURE NEGATIVE SEPSIS,Opposites,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 14:23:18,,1323596171,7/15/2014 14:22:51,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CONTRAINDICATES],[CONTRAINDICATES],and,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 14:30:47,,1323598452,7/15/2014 14:30:37,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],absolute,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 15:20:41,,1323619938,7/15/2014 15:19:51,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Different conditions,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 15:24:40,,1323622698,7/15/2014 15:23:30,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],and,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 16:04:14,,1323652328,7/15/2014 16:03:35,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],SEPSIS,n/a,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 16:31:22,,1323679549,7/15/2014 16:31:08,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221034,7/15/2014 16:46:52,,1323697440,7/15/2014 16:44:33,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[OTHER],[OTHER],was,N/A,98,34,120,55,-1,RO-cause_of,900401-FS1,Percentage of CD4(+) was lower in CULTURE PROVEN SEPSIS and absolute count of CD4(+) was lower in CULTURE NEGATIVE SEPSIS (p.,CULTURE NEGATIVE SEPSIS,CULTURE PROVEN SEPSIS
503221035,7/15/2014 10:05:51,,1323474280,7/15/2014 10:05:37,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,na,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 10:09:11,,1323476217,7/15/2014 10:08:47,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 10:09:18,,1323476289,7/15/2014 10:08:23,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS,Associated With,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 11:01:49,,1323510513,7/15/2014 11:01:32,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],including,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 11:02:13,,1323510762,7/15/2014 11:01:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[MANIFESTATION],[MANIFESTATION],had residual/recurrent,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 11:20:42,,1323524270,7/15/2014 11:20:30,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[PART_OF],[PART_OF],including,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 12:07:17,,1323549424,7/15/2014 12:06:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],including,n/a,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 12:12:10,,1323551155,7/15/2014 12:11:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/a,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 12:45:39,,1323563932,7/15/2014 12:44:46,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SYMPTOM],[SYMPTOM],including,n/a,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 12:47:06,,1323564522,7/15/2014 12:46:31,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 13:19:33,,1323576762,7/15/2014 13:18:48,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],including,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 14:54:56,,1323607674,7/15/2014 14:54:19,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[SYMPTOM],[SYMPTOM],including,N/A,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 15:43:52,,1323636740,7/15/2014 15:43:38,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DYSPLASIA HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS,n/a,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 16:48:28,,1323699129,7/15/2014 16:47:43,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",residual/recurrent,NA,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221035,7/15/2014 16:57:21,,1323708993,7/15/2014 16:55:56,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,n/a,51,71,59,117,-1,RO-disease_has_finding,901611-FS1,"Fifty five patients (27.5%) had residual/recurrent DYSPLASIA including 36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS (66% 14 low grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",DYSPLASIA,36 HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESIONS
503221036,7/15/2014 10:13:40,,1323478576,7/15/2014 10:13:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 10:57:26,,1323507863,7/15/2014 10:57:01,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with and,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 11:11:53,,1323518710,7/15/2014 11:10:40,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are two different diseases with no relation to each other.,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 11:58:36,,1323546216,7/15/2014 11:58:12,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],be associated with and,n/a,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 12:24:10,,1323555868,7/15/2014 12:23:15,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE DEMENTIA (IBMPFD),n/a,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 13:10:06,,1323573565,7/15/2014 13:09:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 13:59:03,,1323589454,7/15/2014 13:58:38,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,none,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 14:30:26,,1323598312,7/15/2014 14:30:17,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],chromosome,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 15:19:50,,1323619433,7/15/2014 15:18:17,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,separate conditions,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 16:24:52,,1323671137,7/15/2014 16:24:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 16:45:39,,1323696053,7/15/2014 16:44:42,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 16:51:10,,1323702087,7/15/2014 16:50:46,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated,NA,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 17:03:56,,1323716260,7/15/2014 17:03:33,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[LOCATION],[LOCATION],"bone, frontotemporal",n/a,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 17:07:20,,1323719292,7/15/2014 17:06:37,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[MANIFESTATION],[MANIFESTATION],and,n/a,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221036,7/15/2014 17:07:52,,1323719728,7/15/2014 17:06:34,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,115,196,162,213,-1,RO-has_manifestation,906075-FS1,"Mutations in the valosin containing protein (VCP) on chromosome 9p13 p12 were recently found to be associated with HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE of the bone, and frontotemporal DEMENTIA (IBMPFD)",HEREDITARY INCLUSION BODY MYOPATHY PAGET DISEASE,DEMENTIA (IBMPFD)
503221037,7/15/2014 09:57:14,,1323467270,7/15/2014 09:55:53,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,[OTHER],[OTHER],Monogenic stroke disorders include,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 10:06:41,,1323474768,7/15/2014 10:06:19,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],subcortical infarcts and,na,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 10:13:29,,1323478492,7/15/2014 10:12:02,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],(CADASIL CEREBRAL AUTOSOMAL RECESSIVE LEUKOENCEPHALOPATHY,Associated With,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 11:04:24,,1323512224,7/15/2014 11:03:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include conditions such as,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 11:09:12,,1323516690,7/15/2014 11:08:50,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 11:20:55,,1323524392,7/15/2014 11:20:00,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],include,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 12:14:43,,1323552253,7/15/2014 12:14:24,instagc,1,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include conditions such as,N/a,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 12:23:41,,1323555665,7/15/2014 12:22:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with subcortical infarcts and,n/a,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 12:45:38,,1323563909,7/15/2014 12:44:45,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],infarcts infarcts,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 12:48:17,,1323565167,7/15/2014 12:47:48,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],arteriopathy,asd,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 13:40:50,,1323584036,7/15/2014 13:40:21,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],conditions,na,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 14:08:41,,1323591999,7/15/2014 14:07:59,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 14:12:59,,1323593186,7/15/2014 14:12:23,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],conditions such as,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 14:20:55,,1323595493,7/15/2014 14:20:39,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221037,7/15/2014 14:48:58,,1323605446,7/15/2014 14:48:18,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[IS_A],[IS_A],include conditions,N/A,226,145,244,182,-1,RO-has_manifestation,906350-FS1,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL CEREBRAL AUTOSOMAL RECESSIVE arteriopathy with subcortical infarcts and LEUKOENCEPHALOPATHY (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",LEUKOENCEPHALOPATHY,(CADASIL CEREBRAL AUTOSOMAL RECESSIVE
503221038,7/15/2014 10:36:30,,1323493515,7/15/2014 10:35:56,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[TREATS],[TREATS],FOSPHENYTOIN STATUS EPILEPTICUS: improved tolerability,Treats,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 11:24:16,,1323526284,7/15/2014 11:23:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[CAUSES],[CAUSES],with improved,N/A,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 11:29:52,,1323529316,7/15/2014 11:29:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],improved tolerability,N/A,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 11:40:57,,1323535796,7/15/2014 11:40:30,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],FOSPHENYTOIN STATUS EPILEPTICUS:,n/a,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 11:51:42,,1323542287,7/15/2014 11:51:21,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[TREATS],[TREATS],FOSPHENYTOIN in patients with STATUS EPILEPTICUS:,n/a,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 12:21:05,,1323554789,7/15/2014 12:20:35,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[TREATS],[TREATS],improved,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 12:34:29,,1323559602,7/15/2014 12:34:09,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],improved tolerability,n/a,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 12:40:16,,1323561790,7/15/2014 12:39:37,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],patients,N/A,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 13:43:34,,1323584885,7/15/2014 13:43:11,clixsense,1,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,Na,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 13:54:04,,1323587896,7/15/2014 13:53:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],in patients with,n/a,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 14:25:07,,1323596688,7/15/2014 14:24:36,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],with,N/A,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 14:28:51,,1323597885,7/15/2014 14:28:33,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],improved tolerability,N/A,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 15:28:59,,1323625678,7/15/2014 15:28:36,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],improved tolerability,N/A,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 16:14:45,,1323660819,7/15/2014 16:14:28,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],improved tolerability,n/a,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221038,7/15/2014 16:56:21,,1323707726,7/15/2014 16:55:42,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[TREATS],[TREATS],improved,NA,44,0,61,12,1,RO-may_treat,907563-FS1,FOSPHENYTOIN and phenytoin in patients with STATUS EPILEPTICUS: improved tolerability versus increased costs.,STATUS EPILEPTICUS,FOSPHENYTOIN
503221039,7/15/2014 10:02:22,,1323471538,7/15/2014 10:02:02,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],venipuncture,na,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 10:13:39,,1323478561,7/15/2014 10:12:57,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[TREATS],[TREATS],underwent a,na,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 10:47:23,,1323501000,7/15/2014 10:46:38,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG] [PREVENTS],"[PREVENTS]
[DIAGNOSE_BY_TEST_OR_DRUG]",underwent a venipuncture for,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 10:54:47,,1323506291,7/15/2014 10:54:11,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],venipuncture for TOTAL THYROXINE triiodothyronine resin uptake,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 11:15:57,,1323521212,7/15/2014 11:14:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],performed by,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 11:30:46,,1323529909,7/15/2014 11:30:17,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underwent a venipuncture for,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 11:33:12,,1323531290,7/15/2014 11:32:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],resin uptake,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 11:57:59,,1323545847,7/15/2014 11:56:14,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],focused on symptoms of,n/a,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 12:05:32,,1323548872,7/15/2014 12:05:16,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[TREATS],[TREATS],underwent a venipuncture,n/a,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 12:13:25,,1323551672,7/15/2014 12:12:28,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],THYROID DISEASE TOTAL THYROXINE,n/a,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 12:38:25,,1323561181,7/15/2014 12:37:31,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],underwent,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 13:16:28,,1323575699,7/15/2014 13:15:58,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],and underwent,N/A,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 13:51:04,,1323587067,7/15/2014 13:50:40,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],underwent,none,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 15:34:55,,1323629957,7/15/2014 15:34:28,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221039,7/15/2014 16:05:34,,1323653500,7/15/2014 16:05:07,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],venipuncture for,n/a,154,203,168,218,1,RO-may_diagnose,906870-FS1,"Each patient had a physical examination performed by his or her primary care provider, was given a standardized questionnaire that focused on symptoms of THYROID DISEASE and underwent a venipuncture for TOTAL THYROXINE triiodothyronine resin uptake and thyrotropin (TSH) concentration.",THYROID DISEASE,TOTAL THYROXINE
503221040,7/15/2014 09:55:14,,1323465554,7/15/2014 09:54:57,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],diagnosis,na,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 10:09:13,,1323476228,7/15/2014 10:08:47,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,na,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 10:40:52,,1323496328,7/15/2014 10:39:40,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis MPS II was,manifestation/symptom,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 11:15:38,,1323521062,7/15/2014 11:15:25,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 11:32:25,,1323530826,7/15/2014 11:30:45,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,Having one condition already doesn't mean that the second is related to it.,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 11:37:33,,1323533818,7/15/2014 11:37:03,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],WITH MARKED CLINICAL KYPHOSIS IN WHOM THE MPS II cells.,n/a,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 12:06:36,,1323549222,7/15/2014 12:06:23,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,n/a,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 12:15:51,,1323552616,7/15/2014 12:15:10,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],by demonstrating a severe deficiency of serum,We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 14:20:08,,1323595300,7/15/2014 14:19:42,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,[DIAGNOSE_BY_TEST_OR_DRUG],16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 14:28:26,,1323597743,7/15/2014 14:28:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],WHOM,N/A,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 14:29:00,,1323597898,7/15/2014 14:28:14,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,Na,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 16:11:43,,1323658374,7/15/2014 16:10:43,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis of,N/A,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 16:23:39,,1323669863,7/15/2014 16:23:02,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],corrected,N/A,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 16:35:51,,1323684650,7/15/2014 16:35:21,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221040,7/15/2014 16:45:36,,1323695979,7/15/2014 16:44:30,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",diagnosis,NA,16,71,56,77,-1,RO-has_manifestation,906479-FS1,"We report a boy WITH MARKED CLINICAL KYPHOSIS IN WHOM THE diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",WITH MARKED CLINICAL KYPHOSIS IN WHOM THE,MPS II
503221041,7/15/2014 09:58:47,,1323468722,7/15/2014 09:58:26,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],displayed,na,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 10:12:02,,1323477643,7/15/2014 10:11:15,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION],[MANIFESTATION],FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS,manifestation,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 10:12:27,,1323477886,7/15/2014 10:11:56,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 10:14:14,,1323478973,7/15/2014 10:13:56,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[SIDE_EFFECT],[SIDE_EFFECT],displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 10:16:40,,1323480515,7/15/2014 10:16:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 10:50:29,,1323503369,7/15/2014 10:49:26,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [SYMPTOM],"[CAUSES]
[SYMPTOM]",displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 11:04:44,,1323512619,7/15/2014 11:04:25,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 11:04:45,,1323512639,7/15/2014 11:04:30,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],displayed,n/a,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 11:17:02,,1323521917,7/15/2014 11:16:49,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[SIDE_EFFECT],[SIDE_EFFECT],displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 11:33:36,,1323531541,7/15/2014 11:33:05,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],defined by,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 11:39:12,,1323534819,7/15/2014 11:38:43,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],FIBROMYALGIA SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS,n/a,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 11:56:18,,1323545006,7/15/2014 11:55:55,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],displayed,n/a,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 12:32:33,,1323558896,7/15/2014 12:31:16,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 12:35:04,,1323559825,7/15/2014 12:34:04,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[MANIFESTATION],[MANIFESTATION],displayed,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221041,7/15/2014 12:48:44,,1323565362,7/15/2014 12:48:28,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,N/A,34,11,83,23,-1,RO-has_definitional_manifestation,904698-FS1,"Women with FIBROMYALGIA displayed SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",SIGNIFICANTLY LOWER PRESSURE PAIN THRESHOLDS AT 18,FIBROMYALGIA
503221042,7/15/2014 09:59:48,,1323469530,7/15/2014 09:59:35,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],reliable test,na,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 10:53:43,,1323505612,7/15/2014 10:53:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reliable test screening test,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 10:59:08,,1323508810,7/15/2014 10:58:50,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reliable test of,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 11:04:38,,1323512538,7/15/2014 11:04:24,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reliable test,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 11:29:12,,1323528996,7/15/2014 11:28:56,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test of,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 11:50:58,,1323541720,7/15/2014 11:50:41,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY",n/a,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 12:16:41,,1323552933,7/15/2014 12:16:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"is a simple, safe, and reliable test of",N/a,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 12:52:23,,1323566789,7/15/2014 12:52:09,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],in,dsa,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 14:05:20,,1323591123,7/15/2014 14:04:56,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,none,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 14:54:49,,1323607640,7/15/2014 14:54:15,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reliable test,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 15:25:59,,1323623543,7/15/2014 15:25:01,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],test of,n/a,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 15:38:17,,1323632518,7/15/2014 15:38:04,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RECTAL GLUTEN CHALLENGE and GLUTEN SENSITIVITY,n/a,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 16:12:42,,1323659111,7/15/2014 16:12:12,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[IS_A],[IS_A],is a,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 16:48:53,,1323699555,7/15/2014 16:48:15,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],reliable test screening test,N/A,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221042,7/15/2014 16:54:28,,1323705606,7/15/2014 16:53:59,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[TREATS],[TREATS],reliable test treated,n/a,0,64,22,82,-1,RO-has_causative_agent,903521-FS1,"RECTAL GLUTEN CHALLENGE is a simple, safe, and reliable test of GLUTEN SENSITIVITY both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",RECTAL GLUTEN CHALLENGE,GLUTEN SENSITIVITY
503221043,7/15/2014 09:57:49,,1323467815,7/15/2014 09:57:36,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],evaluation,na,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 10:14:46,,1323479294,7/15/2014 10:14:26,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation for,N/A,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 10:39:26,,1323495524,7/15/2014 10:37:52,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [OTHER],"[ASSOCIATED_WITH]
[OTHER]",evaluation for SECONDARY HYPERTENSION should be deferred,N/A,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 11:18:38,,1323523065,7/15/2014 11:18:13,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation for,n/a,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 11:38:39,,1323534564,7/15/2014 11:38:13,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSIVE CRISIS SECONDARY HYPERTENSION,n/a,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 11:55:31,,1323544572,7/15/2014 11:55:14,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation for,n/a,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 11:56:14,,1323544957,7/15/2014 11:54:46,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],evaluation for,n/a,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 12:36:27,,1323560383,7/15/2014 12:35:06,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[ASSOCIATED_WITH],[ASSOCIATED_WITH],evaluation,N/A,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 12:50:15,,1323565953,7/15/2014 12:49:57,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],SECONDARY HYPERTENSION,dsa,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 12:58:45,,1323569222,7/15/2014 12:58:12,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation,N/A,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 13:02:51,,1323570979,7/15/2014 13:02:29,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,Na,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 13:04:45,,1323571539,7/15/2014 13:04:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation for,N/A,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 13:51:08,,1323587086,7/15/2014 13:50:37,elite,1.0,28276268,USA,CA,San Rafael,98.210.32.37,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evaluation for,[DIAGNOSE_BY_TEST_OR_DRUG],38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 13:57:44,,1323589029,7/15/2014 13:57:19,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],for,none,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221043,7/15/2014 15:22:54,,1323621491,7/15/2014 15:22:16,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],evaluation for,N/A,38,3,59,22,-1,RO-disease_has_finding,901585-FS1,In HYPERTENSIVE CRISIS evaluation for SECONDARY HYPERTENSION should be deferred until the patient is stable.,SECONDARY HYPERTENSION,HYPERTENSIVE CRISIS
503221044,7/15/2014 11:06:12,,1323513818,7/15/2014 11:05:57,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"testing,",N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 11:17:22,,1323522274,7/15/2014 11:17:03,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 11:28:35,,1323528706,7/15/2014 11:28:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Differential diagnosis of involves:,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 11:43:37,,1323537507,7/15/2014 11:43:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Differential diagnosis of CUSHING'S SYNDROME involves: METYRAPONE TESTING,n/a,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 12:11:14,,1323550871,7/15/2014 12:10:35,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 12:29:14,,1323557757,7/15/2014 12:28:20,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],involves: TESTING,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 12:36:28,,1323560404,7/15/2014 12:35:43,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"testing,",N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 12:40:58,,1323562043,7/15/2014 12:40:25,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis involves:,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 12:49:09,,1323565563,7/15/2014 12:48:45,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Differential diagnosis of CUSHING'S SYNDROME involves: METYRAPONE TESTING TESTING,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 12:51:45,,1323566527,7/15/2014 12:51:19,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SIDE_EFFECT],[SIDE_EFFECT],"ACTH and finally, bilateral simultaneous petrosal sinus sampling",asdwad,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 13:06:34,,1323572275,7/15/2014 13:06:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Differential diagnosis of CUSHING'S SYNDROME involves: METYRAPONE TESTING,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 13:13:40,,1323574705,7/15/2014 13:13:00,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"involves: testing,",N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 14:21:57,,1323595793,7/15/2014 14:21:43,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 14:48:17,,1323605186,7/15/2014 14:47:56,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"dexamethasone testing,",N/A,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221044,7/15/2014 15:41:50,,1323635056,7/15/2014 15:41:26,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUSHING'S SYNDROME ACTH dexamethasone,n/a,26,121,43,147,1,RO-may_diagnose,906876-FS1,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE TESTING TESTING with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",CUSHING'S SYNDROME,METYRAPONE TESTING TESTING
503221045,7/15/2014 09:59:03,,1323468970,7/15/2014 09:58:48,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],treatment,na,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 10:16:51,,1323480681,7/15/2014 10:16:30,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],in the treatment of,N/A,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 11:03:14,,1323511416,7/15/2014 11:03:00,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],treatment,N/A,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 11:23:10,,1323525619,7/15/2014 11:22:25,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],treatment of,N/A,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 11:40:26,,1323535542,7/15/2014 11:39:55,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[TREATS],[TREATS],CREAM VERSUS ORAL METRONIDAZOLE BACTERIAL VAGINOSIS:,n/a,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 12:10:34,,1323550593,7/15/2014 12:10:13,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n/a,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 12:10:51,,1323550708,7/15/2014 12:09:01,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[TREATS],[TREATS],CREAM VERSUS ORAL METRONIDAZOLE BACTERIAL VAGINOSIS:,n/a,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 12:20:29,,1323554488,7/15/2014 12:20:04,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],treatment,is treated by,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 12:46:07,,1323564100,7/15/2014 12:45:55,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],treatment of,n/a,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 13:46:35,,1323585851,7/15/2014 13:46:16,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],treatment of,N/A,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 13:52:15,,1323587378,7/15/2014 13:51:49,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],treatment,none,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 15:07:40,,1323613193,7/15/2014 15:07:21,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[TREATS],[TREATS],in the treatment of,N/A,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 16:00:45,,1323649536,7/15/2014 16:00:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment of,n/a,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 16:28:11,,1323675429,7/15/2014 16:27:00,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],treatment,N/A,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221045,7/15/2014 16:44:28,,1323694538,7/15/2014 16:43:55,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[TREATS],[TREATS],treatment,NA,109,57,127,88,1,RO-may_treat,907603-FS1,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal CREAM VERSUS ORAL METRONIDAZOLE in the treatment of BACTERIAL VAGINOSIS: a prospective double blind clinical trial.",BACTERIAL VAGINOSIS,CREAM VERSUS ORAL METRONIDAZOLE
503221046,7/15/2014 10:14:25,,1323479075,7/15/2014 10:14:08,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associations between,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 10:58:07,,1323508299,7/15/2014 10:57:07,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",there were positive associations between,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 11:04:23,,1323512208,7/15/2014 11:04:05,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],associations,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 11:05:48,,1323513470,7/15/2014 11:04:45,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive associations,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 11:33:44,,1323531650,7/15/2014 11:33:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AMYLOID,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 11:49:48,,1323540885,7/15/2014 11:48:54,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],development AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS,n/a,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 12:08:30,,1323549843,7/15/2014 12:07:18,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and there were,n/a,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 12:18:31,,1323553631,7/15/2014 12:18:17,instagc,1.0,18960682,GBR,"","",86.29.147.112,[TREATS],[TREATS],positive associations between,N/a,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 12:23:54,,1323555766,7/15/2014 12:23:05,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],positive associations between,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 12:26:37,,1323556801,7/15/2014 12:24:57,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS] [ASSOCIATED_WITH],"[TREATS]
[ASSOCIATED_WITH]",development of,n/a,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 12:51:01,,1323566227,7/15/2014 12:50:29,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AMYLOID ARTHROPATHY associations AMYLOIDOSIS,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 13:07:01,,1323572425,7/15/2014 13:06:46,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were positive associations,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 14:51:18,,1323606270,7/15/2014 14:50:58,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[ASSOCIATED_WITH],[ASSOCIATED_WITH],positive associations between,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 15:41:25,,1323634761,7/15/2014 15:39:01,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AMYLOID ARTHROPATHY AMYLOIDOSIS,n/a,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221046,7/15/2014 16:30:25,,1323678338,7/15/2014 16:30:04,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,N/A,74,139,92,150,-1,RO-cause_of,900376-FS1,"In conclusion, it was observed that vitamin A enhanced the development of AMYLOID ARTHROPATHY and there were positive associations between AMYLOIDOSIS increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",AMYLOID ARTHROPATHY,AMYLOIDOSIS
503221047,7/15/2014 10:42:12,,1323497313,7/15/2014 10:41:30,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES],[CAUSES],caused by,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 11:02:34,,1323510939,7/15/2014 11:02:14,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],caused by,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 11:05:13,,1323512977,7/15/2014 11:04:59,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],caused,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 11:21:40,,1323524836,7/15/2014 11:21:22,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 11:25:25,,1323526841,7/15/2014 11:24:31,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,"They both have to do with the causation of Down Syndrome, but not each other.",62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 12:49:54,,1323565878,7/15/2014 12:49:40,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],(DS),dsa,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 13:13:47,,1323574759,7/15/2014 13:13:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[CAUSES],[CAUSES],and caused by,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 13:20:02,,1323576906,7/15/2014 13:19:34,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],is the most frequent genetic disorder with,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 13:23:45,,1323578148,7/15/2014 13:22:04,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],caused by,na,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 14:05:40,,1323591217,7/15/2014 14:05:12,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[CAUSES],[CAUSES],caused by,[CAUSES],62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 14:28:17,,1323597705,7/15/2014 14:28:04,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],caused,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 14:29:45,,1323598092,7/15/2014 14:29:02,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],caused by,Na,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 14:54:14,,1323607426,7/15/2014 14:53:44,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],caused by,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 15:07:58,,1323613301,7/15/2014 15:07:42,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[CAUSES],[CAUSES],caused by,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221047,7/15/2014 15:32:20,,1323628072,7/15/2014 15:31:47,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[MANIFESTATION],[MANIFESTATION],caused by,N/A,62,95,79,105,1,RO-has_manifestation,906118-FS1,Down syndrome (DS) is the most frequent genetic disorder with MENTAL RETARDATION and caused by TRISOMY 21,MENTAL RETARDATION,TRISOMY 21
503221048,7/15/2014 10:11:17,,1323477209,7/15/2014 10:10:49,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[CONTRAINDICATES],[CONTRAINDICATES],supersensitivity to,na,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 11:07:04,,1323514726,7/15/2014 11:06:39,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],denervation,N/A,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 11:13:28,,1323519745,7/15/2014 11:12:23,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SIDE_EFFECT],[SIDE_EFFECT],supersensitivity,not applicable,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 11:35:57,,1323532925,7/15/2014 11:35:22,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],as evidenced by positive denervation supersensitivity to,n/a,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 11:45:52,,1323538691,7/15/2014 11:44:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],response of urethral pressure administration of an alpha stimulant,n/a,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 12:18:14,,1323553536,7/15/2014 12:17:55,instagc,1.0,18960682,GBR,"","",86.29.147.112,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evidenced by positive denervation supersensitivity to,N/a,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 12:21:42,,1323554980,7/15/2014 12:20:30,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],supersensitivity,N/A,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 12:53:36,,1323567172,7/15/2014 12:53:19,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],alpha positive denervation supersensitivity PARASYMPATHOMIMETIC,dsa,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 14:01:55,,1323590290,7/15/2014 14:01:22,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],evidenced,none,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 14:24:03,,1323596448,7/15/2014 14:23:32,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],evidenced,N/A,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 15:12:50,,1323615670,7/15/2014 15:11:03,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],evidenced by positive denervation supersensitivity to,N/A,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 15:39:00,,1323633074,7/15/2014 15:38:39,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC NEUROGENIC PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE,n/a,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 16:03:01,,1323651364,7/15/2014 16:02:17,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],supersensitivity to,n/a,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 16:31:39,,1323679885,7/15/2014 16:31:23,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],between,N/A,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221048,7/15/2014 16:42:58,,1323692930,7/15/2014 16:41:38,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was compared group of control patients.,N/A,126,211,152,251,1,RO-may_diagnose,906758-FS1,The response of urethral pressure to administration of an alpha stimulant was compared between a group of eight patients with CHRONIC NEUROGENIC BLADDERS as evidenced by positive denervation supersensitivity to PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE and a group of ten control patients.,CHRONIC NEUROGENIC BLADDERS,PARASYMPATHOMIMETIC BETHANECHOL CHLORIDE
503221049,7/15/2014 09:58:05,,1323468031,7/15/2014 09:57:50,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[MANIFESTATION],[MANIFESTATION],exclude possibility,na,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 10:11:56,,1323477592,7/15/2014 10:11:13,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],does not exclude the possibility of,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 10:18:43,,1323481903,7/15/2014 10:18:23,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",does not exclude the possibility of,na,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 11:11:54,,1323518723,7/15/2014 11:11:38,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],does not exclude,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 11:14:51,,1323520567,7/15/2014 11:13:29,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[MANIFESTATION] [CONTRAINDICATES],"[MANIFESTATION]
[CONTRAINDICATES]",condition associated exclude possibility,not applicable,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 11:26:15,,1323527235,7/15/2014 11:25:47,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],does not exclude the possibility of,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 11:55:03,,1323544278,7/15/2014 11:54:29,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[CONTRAINDICATES],[CONTRAINDICATES],THROMBOCYTOSIS ESSENTIAL THROMBOCYTHEMIA,n/a,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 12:14:23,,1323552069,7/15/2014 12:14:08,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],condition associated with,N/a,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 12:43:55,,1323563182,7/15/2014 12:42:02,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],does not exclude the possibility,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 12:57:37,,1323568658,7/15/2014 12:57:19,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],presence are,asd,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 13:22:29,,1323577781,7/15/2014 13:21:59,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],does not exclude the possibility of,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 13:57:01,,1323588889,7/15/2014 13:56:04,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],does not exclude the possibility of,n/a,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 14:06:00,,1323591291,7/15/2014 14:05:29,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],associated with,none,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 14:31:27,,1323598632,7/15/2014 14:31:10,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[SYMPTOM],[SYMPTOM],does not exclude the possibility of,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221049,7/15/2014 14:47:06,,1323604708,7/15/2014 14:46:37,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],presence of a condition associated with reactive,N/A,62,113,75,138,-1,RO-disease_has_finding,901625-FS1,"However, the presence of a condition associated with reactive THROMBOCYTOSIS does not exclude the possibility of ESSENTIAL THROMBOCYTHEMIA if the first three criteria are met.",THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA
503221050,7/15/2014 09:56:17,,1323466416,7/15/2014 09:56:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],used graft,na,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 10:07:35,,1323475248,7/15/2014 10:07:04,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],was used,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 10:15:12,,1323479597,7/15/2014 10:14:34,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[TREATS],[TREATS],versus,na,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 10:19:42,,1323482706,7/15/2014 10:19:18,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],was used as graft,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 10:44:36,,1323499060,7/15/2014 10:43:19,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[TREATS],[TREATS],was used as,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 11:08:34,,1323516032,7/15/2014 11:08:14,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],was used,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 11:10:39,,1323517776,7/15/2014 11:10:01,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,There are no words that indicate a relationship between the two.,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 11:12:37,,1323519247,7/15/2014 11:11:52,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],versus,n/a,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 11:25:15,,1323526794,7/15/2014 11:24:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[TREATS],[TREATS],was used,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 12:31:06,,1323558365,7/15/2014 12:30:29,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CONTRAINDICATES],[CONTRAINDICATES],MYCOPHENOLATE MOFETIL HOST DISEASE (GVHD) PROPHYLAXIS.,n/a,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 12:44:44,,1323563518,7/15/2014 12:43:42,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],HOST DISEASE,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 12:46:37,,1323564365,7/15/2014 12:46:08,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],used as graft versus,n/a,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 12:50:03,,1323565916,7/15/2014 12:49:38,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],MYCOPHENOLATE MOFETIL was used versus HOST DISEASE (GVHD) PROPHYLAXIS.,Alternative,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 13:10:50,,1323573779,7/15/2014 13:10:09,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],was used as graft versus,N/A,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221050,7/15/2014 13:26:21,,1323578999,7/15/2014 13:25:44,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH],[ASSOCIATED_WITH],combined with,na,101,37,131,58,1,RO-may_prevent,907052-FS1,"Ciclosporine, alone or combined with MYCOPHENOLATE MOFETIL or methotrexate, was used as graft versus HOST DISEASE (GVHD) PROPHYLAXIS.",HOST DISEASE (GVHD) PROPHYLAXIS,MYCOPHENOLATE MOFETIL
503221051,7/15/2014 10:03:26,,1323472405,7/15/2014 10:02:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],such as,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 10:10:47,,1323476996,7/15/2014 10:10:25,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],mutation in,na,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 11:23:07,,1323525603,7/15/2014 11:20:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],such as,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 11:24:25,,1323526325,7/15/2014 11:24:13,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],such as,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 11:36:59,,1323533492,7/15/2014 11:36:32,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SINGLE GENE OBESITY SYNDROME BARDET BIEDL SYNDROME,n/a,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 11:52:46,,1323543152,7/15/2014 11:51:06,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],will manifest itself as a result of a or,n/a,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 12:24:38,,1323556036,7/15/2014 12:23:55,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],such as,is an example,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 12:31:47,,1323558586,7/15/2014 12:31:11,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SINGLE GENE OBESITY SYNDROME BARDET BIEDL SYNDROME,n/a,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 12:37:26,,1323560769,7/15/2014 12:37:00,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[ASSOCIATED_WITH],[ASSOCIATED_WITH],obesity will manifest itself as SINGLE GENE OBESITY SYNDROME or BARDET BIEDL SYNDROME,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 13:08:08,,1323572818,7/15/2014 13:06:41,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[IS_A],[IS_A],such as or,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 13:24:19,,1323578393,7/15/2014 13:23:46,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],manifest itself,naa,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 13:27:59,,1323579658,7/15/2014 13:27:38,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[PART_OF],[PART_OF],such as,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 14:05:40,,1323591221,7/15/2014 14:04:43,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[IS_A],[IS_A],such as,n/a,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 14:26:43,,1323597170,7/15/2014 14:26:29,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],such as,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221051,7/15/2014 14:28:52,,1323597886,7/15/2014 14:28:44,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],SINGLE,N/A,75,137,102,158,-1,RO-has_manifestation,906084-FS1,"23   Rarely, childhood onset obesity will manifest itself as a result of a SINGLE GENE OBESITY SYNDROME such as Prader Willi syndrome or BARDET BIEDL SYNDROME or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro opiomelanocortin ( POMC ) gene, which makes ? melanocortin stimulating hormone (? MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",SINGLE GENE OBESITY SYNDROME,BARDET BIEDL SYNDROME
503221052,7/15/2014 10:07:19,,1323475108,7/15/2014 10:06:35,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[LOCATION],[LOCATION],ACUTE CONTACT DERMATITIS causes many different lesions SKIN,Location,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 10:09:34,,1323476380,7/15/2014 10:09:09,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[LOCATION],[LOCATION],causes many different lesions on,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 10:53:23,,1323505396,7/15/2014 10:53:08,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],on the,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 11:15:16,,1323520780,7/15/2014 11:14:52,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],causes,not applicable,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 11:18:40,,1323523087,7/15/2014 11:18:29,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[CAUSES],[CAUSES],causes,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 11:51:14,,1323541922,7/15/2014 11:50:27,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[LOCATION],[LOCATION],lesions on the,n/a,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 12:19:00,,1323553850,7/15/2014 12:18:47,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],causes many,N/a,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 12:45:54,,1323564015,7/15/2014 12:45:40,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[LOCATION],[LOCATION],on the,n/a,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 12:52:42,,1323566876,7/15/2014 12:52:25,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[LOCATION],[LOCATION],DERMATITIS,dsa,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 13:12:22,,1323574306,7/15/2014 13:11:52,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,It causes LESION of the skin. There is no link without the word ''lesion'' added to ''skin''.,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 13:33:03,,1323581341,7/15/2014 13:32:48,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],causes many different lesions on,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 13:57:08,,1323588893,7/15/2014 13:56:49,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[LOCATION],[LOCATION],on,none,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 14:21:08,,1323595576,7/15/2014 14:20:58,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[LOCATION],[LOCATION],on the,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 14:27:38,,1323597482,7/15/2014 14:27:29,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],causes,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221052,7/15/2014 14:56:23,,1323608236,7/15/2014 14:56:07,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],causes many different,N/A,66,4,69,28,1,RO-has_finding_site,905031-FS1,The ACUTE CONTACT DERMATITIS causes many different lesions on the SKIN,SKIN,ACUTE CONTACT DERMATITIS
503221053,7/15/2014 09:57:00,,1323467113,7/15/2014 09:56:47,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],intracavernous injections,na,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 10:54:10,,1323505937,7/15/2014 10:53:44,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],injections were employed.,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 11:55:25,,1323544494,7/15/2014 11:54:58,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"ERECTILE DYSFUNCTION diagnostic purposes, PAPAVERINE/phentolamine were employed.",n/a,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 12:16:24,,1323552819,7/15/2014 12:15:53,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ERECTILE DYSFUNCTION PAPAVERINE/phentolamine,n/a,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 12:18:05,,1323553462,7/15/2014 12:17:08,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"for both diagnostic and therapeutic purposes,",njections of papaverine and the combination PAPAVERINE/phentolamine were employed.,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 12:20:04,,1323554288,7/15/2014 12:19:14,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],injections were employed.,is treated by,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 12:37:42,,1323560889,7/15/2014 12:37:28,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[TREATS],[TREATS],ERECTILE DYSFUNCTION PAPAVERINE/phentolamine were employed.,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 12:37:59,,1323560983,7/15/2014 12:36:29,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],injections papaverine,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 12:43:53,,1323563178,7/15/2014 12:43:23,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],"for diagnostic and therapeutic purposes,",n/a,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 13:52:12,,1323587367,7/15/2014 13:51:55,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],and the combination,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 13:54:53,,1323588142,7/15/2014 13:54:07,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],employed.,none,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 14:22:39,,1323595945,7/15/2014 14:22:07,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for both diagnostic,[DIAGNOSE_BY_TEST_OR_DRUG],3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 14:27:59,,1323597596,7/15/2014 14:27:50,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnostic,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 16:21:07,,1323666861,7/15/2014 16:20:31,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],were employed.,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221053,7/15/2014 16:43:56,,1323693940,7/15/2014 16:43:00,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[TREATS],[TREATS],were employed.,N/A,3,140,22,150,1,RO-may_diagnose,906641-FS1,"In ERECTILE DYSFUNCTION formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination PAPAVERINE/phentolamine were employed.",ERECTILE DYSFUNCTION,PAPAVERINE
503221054,7/15/2014 10:11:21,,1323477220,7/15/2014 10:11:06,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 11:06:21,,1323514004,7/15/2014 11:06:06,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 11:13:29,,1323519748,7/15/2014 11:13:05,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used for testing,n/a,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 11:15:38,,1323521065,7/15/2014 11:15:17,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,not applciable,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 12:12:32,,1323551318,7/15/2014 12:12:07,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,n/a,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 12:23:04,,1323555467,7/15/2014 12:21:42,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 12:43:41,,1323563062,7/15/2014 12:43:15,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 12:51:51,,1323566551,7/15/2014 12:51:36,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 13:09:33,,1323573334,7/15/2014 13:09:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],routinely used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 13:15:33,,1323575371,7/15/2014 13:15:05,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],routinely used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 13:27:15,,1323579351,7/15/2014 13:27:01,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],routinely used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 13:27:24,,1323579410,7/15/2014 13:26:58,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],for testing,na,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 14:03:23,,1323590629,7/15/2014 14:02:56,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],testing,none,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 14:27:49,,1323597558,7/15/2014 14:27:40,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[ASSOCIATED_WITH],[ASSOCIATED_WITH],testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221054,7/15/2014 15:21:20,,1323620443,7/15/2014 15:20:43,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],routinely used for testing,N/A,59,0,83,31,1,RO-may_diagnose,906521-FS1,METHACHOLINE CHLORIDE SOLUTIONS routinely used for testing BRONCHIAL HYPERREACTIVITY have been shown to degrade over time.,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE SOLUTIONS
503221055,7/15/2014 10:18:27,,1323481726,7/15/2014 10:17:37,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[TREATS] [PART_OF],"[TREATS]
[PART_OF]",that the from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 10:48:04,,1323501491,7/15/2014 10:47:08,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[CAUSES],[CAUSES],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 11:01:12,,1323510150,7/15/2014 11:00:44,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 11:09:21,,1323516808,7/15/2014 11:08:47,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[CAUSES],[CAUSES],from,not applicable,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 11:19:03,,1323523388,7/15/2014 11:17:56,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM],[SYMPTOM],suggesting,NA,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 11:19:42,,1323523742,7/15/2014 11:19:20,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],from,n/a,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 11:32:16,,1323530772,7/15/2014 11:31:58,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 11:40:50,,1323535705,7/15/2014 11:40:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,n/a,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 12:33:41,,1323559337,7/15/2014 12:31:54,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[MANIFESTATION],[MANIFESTATION],INCREASED from,n/a,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 13:13:09,,1323574567,7/15/2014 13:13:01,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION],[MANIFESTATION],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 13:21:58,,1323577604,7/15/2014 13:21:33,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 13:30:25,,1323580416,7/15/2014 13:30:09,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 13:30:29,,1323580423,7/15/2014 13:30:02,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [TREATS],"[TREATS]
[SYMPTOM]",from,na,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 14:30:47,,1323598444,7/15/2014 14:30:32,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],from,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221055,7/15/2014 14:50:30,,1323605979,7/15/2014 14:50:05,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],increased palm temperature suggesting that,N/A,95,69,123,89,1,RO-has_finding_site,905157-FS1,Hoku acupuncture also increased palm temperature suggesting that the BLOOD FLOW INCREASED from CUTANEOUS VESSEL VASODILATION.,CUTANEOUS VESSEL VASODILATION,BLOOD FLOW INCREASED
503221056,7/15/2014 09:55:56,,1323466105,7/15/2014 09:55:23,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],By the test we determined development of the syndrome,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 10:12:31,,1323477904,7/15/2014 10:12:07,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,na,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 10:24:03,,1323485345,7/15/2014 10:23:32,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test we determined the development of the syndrome of,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 10:47:45,,1323501272,7/15/2014 10:47:24,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],we determined the development of,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 11:09:59,,1323517319,7/15/2014 11:09:28,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],development of the syndrome,n/a,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 11:19:54,,1323523899,7/15/2014 11:19:30,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,not applicable,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 11:45:32,,1323538444,7/15/2014 11:44:58,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HALOTHANE MALIGNANT HYPERTHERMIA,n/a,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 13:34:45,,1323581925,7/15/2014 13:34:24,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 13:34:52,,1323581942,7/15/2014 13:34:17,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],determined the development,na,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 14:06:56,,1323591554,7/15/2014 14:05:55,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],determined the development of,[DIAGNOSE_BY_TEST_OR_DRUG],71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 14:09:03,,1323592138,7/15/2014 14:08:43,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],development,none,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 14:29:35,,1323598038,7/15/2014 14:29:29,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],syndrome,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 14:51:36,,1323606396,7/15/2014 14:51:20,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test we determined,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 15:30:23,,1323626727,7/15/2014 15:29:53,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],development of the syndrome,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221056,7/15/2014 16:32:05,,1323680339,7/15/2014 16:31:41,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test we determined,N/A,71,7,92,16,1,RO-may_diagnose,906643-FS1,By the HALOTHANE test we determined the development of the syndrome of MALIGNANT HYPERTHERMIA in pigs of the Belgian Landrace breed with body weight of 20 kg.,MALIGNANT HYPERTHERMIA,HALOTHANE
503221057,7/15/2014 10:53:10,,1323505246,7/15/2014 10:52:30,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],which originates from,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 11:09:26,,1323516882,7/15/2014 11:09:00,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],originates,n/a,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 11:27:31,,1323528055,7/15/2014 11:26:21,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[LOCATION],[LOCATION],which originates from,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 11:35:28,,1323532701,7/15/2014 11:35:08,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LYMPHANGIOMA LYMPH VESSELS,n/a,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 12:28:10,,1323557337,7/15/2014 12:27:50,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],originates from,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 12:40:32,,1323561892,7/15/2014 12:39:34,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[CAUSES],[CAUSES],originates from LYMPH VESSELS,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 12:54:50,,1323567598,7/15/2014 12:54:35,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],LYMPHANGIOMA,asd,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 13:29:29,,1323580171,7/15/2014 13:29:01,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],originates,na,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 15:09:29,,1323613940,7/15/2014 15:09:13,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[LOCATION],[LOCATION],originates from,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 15:27:34,,1323624608,7/15/2014 15:27:13,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],originates from,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 15:54:18,,1323644566,7/15/2014 15:53:49,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[LOCATION],[LOCATION],originates from,n/a,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 16:00:23,,1323649211,7/15/2014 16:00:00,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],originates from LYMPH VESSELS,n/a,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 16:31:07,,1323679212,7/15/2014 16:30:48,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[LOCATION],[LOCATION],originates,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 16:48:55,,1323699601,7/15/2014 16:48:29,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[LOCATION] [MANIFESTATION],"[LOCATION]
[MANIFESTATION]",originates,NA,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221057,7/15/2014 16:49:40,,1323700480,7/15/2014 16:48:55,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",originates,N/A,99,20,111,32,1,RO-disease_has_primary_anatomic_site,902202-FS1,"In the oral cavity, LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm which originates from LYMPH VESSELS",LYMPH VESSELS,LYMPHANGIOMA
503221058,7/15/2014 09:58:26,,1323468324,7/15/2014 09:58:05,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 10:09:08,,1323476159,7/15/2014 10:08:44,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Unrelated conditions,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 11:25:26,,1323526873,7/15/2014 11:25:02,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],ERYTHEMATOSUS.,N/A,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 11:31:00,,1323530000,7/15/2014 11:30:47,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[IS_A],[IS_A],and,N/A,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 11:33:10,,1323531251,7/15/2014 11:32:25,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They both have the same treatment but are not related to each other necessarily.,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 12:39:00,,1323561395,7/15/2014 12:38:41,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 12:49:43,,1323565819,7/15/2014 12:49:17,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],and,different conditions,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 12:55:34,,1323567832,7/15/2014 12:55:16,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[IS_A],[IS_A],DISCOID LUPUS ERYTHEMATOSUS,asd,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 14:25:23,,1323596768,7/15/2014 14:25:04,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[TREATS],[TREATS],Treatment of,[TREATS],34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 14:32:32,,1323598984,7/15/2014 14:29:46,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 15:25:34,,1323623308,7/15/2014 15:24:41,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],and,N/A,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 16:09:21,,1323656480,7/15/2014 16:06:24,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LUPUS,n/a,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 16:22:39,,1323668675,7/15/2014 16:22:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 16:51:47,,1323702780,7/15/2014 16:51:11,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,NA,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221058,7/15/2014 16:52:06,,1323703175,7/15/2014 16:51:35,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,34,66,60,94,-1,RO-cause_of,900301-FS1,Lupus Erythematosus  Treatment of DISCOID LUPUS ERYTHEMATOSUS and SYSTEMIC LUPUS ERYTHEMATOSUS.,DISCOID LUPUS ERYTHEMATOSUS,SYSTEMIC LUPUS ERYTHEMATOSUS
503221059,7/15/2014 09:57:09,,1323467204,7/15/2014 09:56:25,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],depending on lobe of origin:,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 10:49:22,,1323502651,7/15/2014 10:48:05,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],seizures,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 11:01:38,,1323510405,7/15/2014 11:00:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seizures lobe of origin:,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 11:17:09,,1323522038,7/15/2014 11:16:26,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[NONE],[NONE],not applicable,They are two different types of seizures.,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 11:22:52,,1323525384,7/15/2014 11:22:34,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],seizures,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 11:26:15,,1323527223,7/15/2014 11:25:17,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],showed,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 11:54:45,,1323544171,7/15/2014 11:53:55,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,They are both types of seizures but have no other relation to each other.,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 12:13:49,,1323551816,7/15/2014 12:13:30,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],seizures,N/a,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 12:15:48,,1323552593,7/15/2014 12:15:06,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TEMPORAL LOBE SEIZURES FRONTAL SEIZURES,n/a,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 12:27:14,,1323557080,7/15/2014 12:26:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],on lobe of origin:,different types of seizures,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 12:50:11,,1323565948,7/15/2014 12:49:00,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],showed distribution,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 12:57:16,,1323568522,7/15/2014 12:56:59,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],and,asd,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 13:06:40,,1323572296,7/15/2014 13:06:02,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[OTHER],[OTHER],depending on lobe of origin:,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 14:04:00,,1323590759,7/15/2014 14:03:32,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],occurred preferentially,none,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221059,7/15/2014 14:26:24,,1323597031,7/15/2014 14:26:05,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[LOCATION],[LOCATION],occurred,N/A,179,103,194,125,-1,RO-has_definitional_manifestation,904867-FS1,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between 1100 and 1700 hours, FRONTAL SEIZURES between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",FRONTAL SEIZURES,TEMPORAL LOBE SEIZURES
503221060,7/15/2014 10:12:43,,1323478003,7/15/2014 10:12:21,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],WHEN,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 11:05:35,,1323513257,7/15/2014 11:05:15,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],THYROID THYROID,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 11:16:47,,1323521720,7/15/2014 11:16:17,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[MANIFESTATION],[MANIFESTATION],risk,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 11:19:18,,1323523550,7/15/2014 11:18:40,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE,n/a,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 11:33:50,,1323531718,7/15/2014 11:33:12,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,n/a,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 11:44:13,,1323537810,7/15/2014 11:43:38,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[LOCATION],[LOCATION],risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND,n/a,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 12:15:09,,1323552417,7/15/2014 12:14:19,clixsense,1.0,27969116,NLD,"","",91.213.37.165,[CAUSES],[CAUSES],there is a risk the irradiated field.,there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 13:09:19,,1323573289,7/15/2014 13:08:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,Completion,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 13:12:12,,1323574286,7/15/2014 13:11:45,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[LOCATION],[LOCATION],EVEN WHEN THE THYROID GLAND IS OUTSIDE,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 13:30:07,,1323580341,7/15/2014 13:29:20,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[PART_OF],[PART_OF],EVEN WHEN,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 14:09:46,,1323592367,7/15/2014 14:09:06,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[CAUSES],[CAUSES],risk,none,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 14:13:47,,1323593365,7/15/2014 14:13:20,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",there is a risk,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 14:26:42,,1323597138,7/15/2014 14:26:09,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],in,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 14:52:20,,1323606603,7/15/2014 14:51:38,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[TREATS],[TREATS],irradiated field.,N/A,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221060,7/15/2014 15:23:35,,1323621924,7/15/2014 15:22:55,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,These are just sentence strands,121,85,161,120,1,RO-disease_has_primary_anatomic_site,902448-FS1,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk OF RADIATION INDUCED THYROID CANCER EVEN WHEN THE THYROID GLAND IS OUTSIDE OF the irradiated field.",EVEN WHEN THE THYROID GLAND IS OUTSIDE OF,OF RADIATION INDUCED THYROID CANCER
503221061,7/15/2014 10:12:59,,1323478229,7/15/2014 10:12:44,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],or,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 11:15:31,,1323520976,7/15/2014 11:15:08,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[IS_A],[IS_A],or,n/a,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 11:50:11,,1323541167,7/15/2014 11:49:49,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[IS_A],[IS_A],HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY mysterious disorder,n/a,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 12:31:52,,1323558627,7/15/2014 12:31:37,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],or,n/a,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 12:42:31,,1323562636,7/15/2014 12:41:34,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[SYMPTOM],[SYMPTOM],TO or,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 12:48:49,,1323565431,7/15/2014 12:47:49,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[OTHER],[OTHER],or,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 13:12:58,,1323574476,7/15/2014 13:12:13,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 14:24:17,,1323596461,7/15/2014 14:23:33,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],is a mysterious disorder that has been reported,[DIAGNOSE_BY_TEST_OR_DRUG],0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 14:27:33,,1323597455,7/15/2014 14:27:18,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[IS_A],[IS_A],or,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 14:29:14,,1323597967,7/15/2014 14:29:04,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[SYMPTOM],[SYMPTOM],that,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 14:39:53,,1323601897,7/15/2014 14:39:24,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,Na,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 15:10:28,,1323614431,7/15/2014 15:10:03,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 16:19:48,,1323665515,7/15/2014 16:19:25,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 16:51:28,,1323702407,7/15/2014 16:49:39,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[OTHER],[OTHER],or,n/a,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221061,7/15/2014 16:54:18,,1323705386,7/15/2014 16:53:08,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[OTHER],[OTHER],or,NA,0,38,33,54,-1,RO-cause_of,900303-FS1,HYPERSENSITIVITY TO MOSQUITO BITES or MOSQUITO ALLERGY is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,HYPERSENSITIVITY TO MOSQUITO BITES,MOSQUITO ALLERGY
503221062,7/15/2014 10:17:36,,1323481198,7/15/2014 10:16:51,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had coincident with,N/A,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 11:30:06,,1323529513,7/15/2014 11:29:54,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 11:50:25,,1323541369,7/15/2014 11:49:11,clixsense,1,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],coincident with,n/a,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 12:20:33,,1323554509,7/15/2014 12:19:43,clixsense,1,27969116,NLD,"","",91.213.37.165,[PART_OF],[PART_OF],with,that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 12:27:48,,1323557216,7/15/2014 12:26:51,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[SYMPTOM],[SYMPTOM],with,N/A,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 12:49:16,,1323565650,7/15/2014 12:48:51,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,two different conditions,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 13:39:38,,1323583690,7/15/2014 13:39:02,neodev,1,18339121,USA,SC,Sumter,173.93.188.194,[CAUSES],[CAUSES],with,na,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 13:51:53,,1323587250,7/15/2014 13:49:29,prodege,1,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],with,N/A,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 13:58:33,,1323589277,7/15/2014 13:58:05,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,none,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 14:27:17,,1323597353,7/15/2014 14:27:04,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 15:31:17,,1323627394,7/15/2014 15:30:43,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Different conditions,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 15:38:38,,1323632749,7/15/2014 15:38:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],GRAVES' DISEASE THYROTOXICOSIS,n/a,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 16:30:45,,1323678779,7/15/2014 16:30:27,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,N/A,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 16:53:57,,1323705029,7/15/2014 16:53:31,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM],[SYMPTOM],with,n/a,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221062,7/15/2014 17:00:24,,1323712597,7/15/2014 16:59:43,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with,n/a,97,118,111,132,-1,RO-cause_of,900029-FS1,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident GRAVES' DISEASE with THYROTOXICOSIS and one had primary myxodema.",GRAVES' DISEASE,THYROTOXICOSIS
503221063,7/15/2014 11:04:04,,1323511957,7/15/2014 11:03:37,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[OTHER],[OTHER],may not have a relation,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 11:31:47,,1323530468,7/15/2014 11:31:01,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[PART_OF],[PART_OF],contribute to,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 11:39:33,,1323534966,7/15/2014 11:36:34,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[NONE],[NONE],n/a,Both terms are related to MMP 7 but not to each other.,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 12:04:57,,1323548681,7/15/2014 12:04:35,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may not have a relation,n/a,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 12:14:15,,1323552002,7/15/2014 12:13:31,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CONTRAINDICATES],[CONTRAINDICATES],UTERINE CARCINOSARCOMA SARCOMATOUS COMPONENTS,n/a,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 12:32:03,,1323558677,7/15/2014 12:31:32,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],UTERINE CARCINOSARCOMA may not have relation to SARCOMATOUS COMPONENTS,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 12:34:08,,1323559498,7/15/2014 12:33:42,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,different conditions,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 12:34:29,,1323559599,7/15/2014 12:33:13,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relation to,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 12:39:55,,1323561732,7/15/2014 12:39:01,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[NONE],[NONE],N/A,It says that it may not have relation to,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 13:22:59,,1323577906,7/15/2014 13:22:29,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[CONTRAINDICATES],[CONTRAINDICATES],while may not have relation to that of,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 13:34:14,,1323581786,7/15/2014 13:32:27,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SIDE_EFFECT] [CONTRAINDICATES],"[CONTRAINDICATES]
[SIDE_EFFECT]",may not have a relation,na,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 14:26:14,,1323596989,7/15/2014 14:25:38,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],while it may not have a relation to,[ASSOCIATED_WITH],168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 14:31:26,,1323598629,7/15/2014 14:31:17,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],carcinomatous,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 14:31:54,,1323598809,7/15/2014 14:31:28,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[ASSOCIATED_WITH],[ASSOCIATED_WITH],may contribute to,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221063,7/15/2014 16:36:47,,1323685735,7/15/2014 16:35:52,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",may contribute,N/A,168,97,189,119,-1,RO-disease_has_finding,901637-FS1,MMP 7 may contribute to the invasive nature or growth capacity of the carcinomatous component of UTERINE CARCINOSARCOMA while it may not have a relation to that of the SARCOMATOUS COMPONENTS,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA
503221064,7/15/2014 10:01:47,,1323471034,7/15/2014 10:01:28,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,[CAUSES],[CAUSES],occur,na,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 10:08:01,,1323475534,7/15/2014 10:07:36,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[CAUSES],[CAUSES],rhinophycomycosis,N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 10:55:33,,1323506809,7/15/2014 10:54:07,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CAUSES] [IS_A] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]
[IS_A]",FUNGUS + osis condition],N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 11:06:39,,1323514321,7/15/2014 11:05:48,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],may occur,n/a,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 11:28:01,,1323528334,7/15/2014 11:27:46,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],FUNGAL,N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 12:40:24,,1323561858,7/15/2014 12:39:56,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[CAUSES],[CAUSES],condition],N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 12:53:53,,1323567268,7/15/2014 12:53:40,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[SYMPTOM],[SYMPTOM],"seaweed,",dsa,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 13:13:36,,1323574700,7/15/2014 13:13:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[PART_OF],[PART_OF],FUNGUS FUNGAL INFECTION,N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 13:40:15,,1323583844,7/15/2014 13:39:40,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",may occur in,na,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 13:51:47,,1323587243,7/15/2014 13:51:08,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],occur,none,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 16:13:21,,1323659695,7/15/2014 16:13:05,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],INFECTION that may occur,n/a,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 16:39:13,,1323688706,7/15/2014 16:38:25,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SIDE_EFFECT],[SIDE_EFFECT],may occur,N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 17:06:36,,1323718602,7/15/2014 17:05:48,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],may,n/a,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 17:08:55,,1323720601,7/15/2014 17:08:18,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.41,[CAUSES],[CAUSES],condition] FUNGAL,N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221064,7/15/2014 17:08:57,,1323720643,7/15/2014 17:08:39,tremorgames,1,19721342,CAN,ON,Ottawa,99.246.56.98,[IS_A],[IS_A],A,N/A,100,130,105,146,-1,RO-has_causative_agent,903937-FS1,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , FUNGUS +  osis , condition] A FUNGAL INFECTION that may occur in humans or animals.",FUNGUS,FUNGAL INFECTION
503221065,7/15/2014 10:14:07,,1323478891,7/15/2014 10:13:41,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[SYMPTOM],[SYMPTOM],characterized by,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 11:02:06,,1323510674,7/15/2014 11:01:50,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[SYMPTOM],[SYMPTOM],characterized,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 11:12:23,,1323519060,7/15/2014 11:11:54,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],characterized by,not applicable,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 11:26:58,,1323527674,7/15/2014 11:26:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 11:48:06,,1323539938,7/15/2014 11:47:27,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],MYELODYSPLASTIC SYNDROMES (MDS) INEFFECTIVE HEMATOPOIESIS,n/a,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 11:54:58,,1323544245,7/15/2014 11:54:33,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYELODYSPLASTIC SYNDROMES are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS,n/a,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 12:04:13,,1323548393,7/15/2014 12:03:43,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],disorders that are characterized,n/a,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 12:10:46,,1323550676,7/15/2014 12:10:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],are characterized by,N/a,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 12:26:24,,1323556703,7/15/2014 12:25:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[SYMPTOM],[SYMPTOM],MYELODYSPLASTIC SYNDROMES (MDS) INEFFECTIVE HEMATOPOIESIS,n/a,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 12:48:40,,1323565338,7/15/2014 12:48:20,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],MYELODYSPLASTIC SYNDROMES,asd,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 13:35:21,,1323582084,7/15/2014 13:34:59,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[SYMPTOM],[SYMPTOM],characterized by,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 15:32:38,,1323628362,7/15/2014 15:32:21,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],characterized,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 16:13:04,,1323659389,7/15/2014 16:12:46,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterized by,n/a,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 16:19:04,,1323664685,7/15/2014 16:17:10,fusioncash,1,21553032,USA,CT,Plainfield,206.53.94.155,[CAUSES] [SYMPTOM] [MANIFESTATION] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]
[ASSOCIATED_WITH]",characterized by,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221065,7/15/2014 16:26:58,,1323673543,7/15/2014 16:26:31,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized,N/A,88,4,112,35,1,RO-disease_has_finding,901915-FS1,The MYELODYSPLASTIC SYNDROMES (MDS) are a family of disorders that are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES (MDS)
503221066,7/15/2014 10:02:27,,1323471574,7/15/2014 10:02:04,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],the most severe of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 10:13:55,,1323478734,7/15/2014 10:13:37,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],the most severe of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 10:46:37,,1323500599,7/15/2014 10:46:06,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[IS_A],[IS_A],most severe of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 11:16:20,,1323521517,7/15/2014 11:15:58,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[PART_OF],[PART_OF],the most severe of,n/a,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 12:04:34,,1323548519,7/15/2014 12:04:14,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[IS_A],[IS_A],most severe of,n/a,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 12:55:58,,1323568009,7/15/2014 12:55:37,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[CAUSES],[CAUSES],PRIMARY HEADACHE CONDITIONS,asd,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 13:42:02,,1323584428,7/15/2014 13:41:28,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[LOCATION] [CAUSES],"[CAUSES]
[LOCATION]",most severe,na,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 15:07:19,,1323613065,7/15/2014 15:07:04,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],the most severe of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 16:10:42,,1323657452,7/15/2014 16:10:11,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[IS_A],[IS_A],the most severe of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 16:57:32,,1323709207,7/15/2014 16:56:49,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[PART_OF] [IS_A],"[IS_A]
[PART_OF]",the,NA,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 17:02:11,,1323714358,7/15/2014 17:01:07,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[MANIFESTATION],[MANIFESTATION],of,n/a,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 17:04:33,,1323716762,7/15/2014 17:04:05,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[SYMPTOM],[SYMPTOM],of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 17:06:25,,1323718423,7/15/2014 17:05:50,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH] [IS_A] [PART_OF],"[ASSOCIATED_WITH]
[IS_A]
[PART_OF]",most severe,n/a,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 17:11:11,,1323722260,7/15/2014 17:10:05,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[DIAGNOSE_BY_TEST_OR_DRUG] [SYMPTOM],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SYMPTOM]","social impairment clinical, studies",N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221066,7/15/2014 17:12:29,,1323723302,7/15/2014 17:11:57,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[IS_A],[IS_A],the most severe of,N/A,36,0,62,16,-1,RO-has_definitional_manifestation,904591-FS1,"CLUSTER HEADACHE the most severe of PRIMARY HEADACHE CONDITIONS for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",PRIMARY HEADACHE CONDITIONS,CLUSTER HEADACHE
503221067,7/15/2014 10:08:46,,1323475932,7/15/2014 10:08:16,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[TREATS],[TREATS],removal of,na,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 11:44:49,,1323538060,7/15/2014 11:42:13,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was methotrexate methotrexate +,n/a,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 12:00:13,,1323546899,7/15/2014 11:59:41,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],was +,n/a,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 12:17:54,,1323553383,7/15/2014 12:17:37,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],was,N/a,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 12:35:50,,1323560085,7/15/2014 12:35:15,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[NONE],[NONE],N/A,Unknown relationship,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 13:10:08,,1323573577,7/15/2014 13:09:16,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[PART_OF],[PART_OF],was,N/A,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 13:38:56,,1323583293,7/15/2014 13:38:09,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[MANIFESTATION],[MANIFESTATION],was methotrexate,na,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 14:00:24,,1323589816,7/15/2014 13:59:40,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],+,none,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 14:27:03,,1323597265,7/15/2014 14:26:44,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],was,N/A,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 15:27:11,,1323624356,7/15/2014 15:26:22,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],methotrexate +,N/A,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 16:15:09,,1323661123,7/15/2014 16:14:13,clixsense,1.0,19500241,USA,NC,Greensboro,174.98.255.13,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CYCLOSPORINE,N/A,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 16:55:54,,1323707236,7/15/2014 16:54:33,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],?,can't,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 17:04:52,,1323716996,7/15/2014 17:04:33,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],+,N/A,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 17:08:14,,1323720059,7/15/2014 17:07:02,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[TREATS],[TREATS],was,N/a,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221067,7/15/2014 17:12:20,,1323723188,7/15/2014 17:11:13,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms found.,0,117,43,129,1,RO-may_prevent,907100-FS1,"GRAFT VERSUS HOST DISEASE (GVHD PROPHYLAXIS was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + CYCLOSPORINE (3 patients), cyclosporine + physical removal of T cells (2 patients.",GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS,CYCLOSPORINE
503221068,7/15/2014 10:00:12,,1323469783,7/15/2014 09:58:55,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG] [OTHER],"[DIAGNOSE_BY_TEST_OR_DRUG]
[OTHER]","isolation not possible, definite PROOF could not be demonstrated.",N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 10:23:32,,1323485064,7/15/2014 10:22:54,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],"isolation was not possible, so that the definite",N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 10:57:01,,1323507622,7/15/2014 10:56:31,instagc,1.0,13763729,USA,"","",75.182.89.225,[PART_OF],[PART_OF],VIRUS VIRAL INFECTION,N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 11:21:20,,1323524653,7/15/2014 11:20:53,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],"isolation was not possible,",n/a,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 11:56:53,,1323545279,7/15/2014 11:56:20,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[CAUSES],[CAUSES],that the definite,n/a,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 12:54:18,,1323567395,7/15/2014 12:53:56,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[MANIFESTATION],[MANIFESTATION],definite PROOF OF VIRAL INFECTION SHML,asd,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 13:08:02,,1323572750,7/15/2014 13:07:47,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[IS_A],[IS_A],VIRUS VIRAL INFECTION,N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 13:27:00,,1323579248,7/15/2014 13:26:33,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],definite PROOF OF,N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 14:15:27,,1323593794,7/15/2014 14:14:54,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"isolation was not possible,",[DIAGNOSE_BY_TEST_OR_DRUG],2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 14:30:31,,1323598363,7/15/2014 14:30:04,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[OTHER],[OTHER],"isolation was not possible,",N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 14:47:54,,1323605035,7/15/2014 14:47:24,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[SYMPTOM],[SYMPTOM],"isolation was not possible,",N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 15:17:40,,1323618227,7/15/2014 15:17:10,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],definite,N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 16:22:20,,1323668312,7/15/2014 16:21:58,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],could not be demonstrated.,N/A,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 16:52:23,,1323703471,7/15/2014 16:50:39,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms were to be found.,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221068,7/15/2014 16:53:58,,1323705038,7/15/2014 16:51:29,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[IS_A],[IS_A],demonstrated.,n/a,2,57,6,91,-1,RO-has_causative_agent,903782-FS1,"A VIRUS isolation was not possible, so that the definite PROOF OF A VIRAL INFECTION OF SHML could not be demonstrated.",VIRUS,PROOF OF A VIRAL INFECTION OF SHML
503221069,7/15/2014 10:10:15,,1323476697,7/15/2014 10:09:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],ATYPICAL PARKINSONISM,N/A,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 11:08:13,,1323515782,7/15/2014 11:07:42,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[PART_OF],[PART_OF],another form,N/A,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 11:16:25,,1323521553,7/15/2014 11:15:39,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[IS_A] [PART_OF],"[IS_A]
[PART_OF]",(MSA.,not applicable,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 11:48:05,,1323539937,7/15/2014 11:47:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[PART_OF],[PART_OF],another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY,n/a,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 12:15:57,,1323552702,7/15/2014 12:15:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],and another form of,N/a,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 12:46:36,,1323564352,7/15/2014 12:46:04,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[OTHER],[OTHER],ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY,both part of the same medical term,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 12:47:52,,1323564983,7/15/2014 12:46:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[IS_A],[IS_A],ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY,n/a,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 12:52:35,,1323566843,7/15/2014 12:52:08,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[OTHER],[OTHER],ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,All one term,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 13:11:07,,1323573858,7/15/2014 13:10:33,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[NONE],[NONE],N/A,It's a completion of the term.,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 13:33:47,,1323581633,7/15/2014 13:33:25,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],and another form of,N/A,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 14:55:11,,1323607747,7/15/2014 14:54:50,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],analysed the relationship between,N/A,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 15:11:03,,1323614748,7/15/2014 15:10:30,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],another form of,N/A,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 16:18:15,,1323663975,7/15/2014 16:17:54,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],another form of,n/a,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 16:26:29,,1323672969,7/15/2014 16:26:13,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],relationship between,N/A,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221069,7/15/2014 16:44:47,,1323694878,7/15/2014 16:43:18,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[IS_A],[IS_A],another form,n/a,123,145,143,168,-1,RO-has_manifestation,906499-FS1,We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of ATYPICAL PARKINSONISM MULTIPLE SYSTEM ATROPHY (MSA.,ATYPICAL PARKINSONISM,MULTIPLE SYSTEM ATROPHY
503221070,7/15/2014 10:01:13,,1323470682,7/15/2014 10:00:58,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],unrecognised syndrome,na,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 10:07:16,,1323475096,7/15/2014 10:07:01,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[CAUSES],[CAUSES],three had,na,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 10:10:11,,1323476661,7/15/2014 10:09:20,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BENIGN CHILDHOOD OCCIPITAL SEIZURES SYMPTOMATIC EPILEPSY,Associated With,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 10:21:32,,1323483911,7/15/2014 10:20:10,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,Two unrelated conditions.,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 11:27:45,,1323528182,7/15/2014 11:27:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[OTHER],[OTHER],SEIZURES,N/A,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 11:42:41,,1323536878,7/15/2014 11:42:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[ASSOCIATED_WITH],[ASSOCIATED_WITH],syndrome of early onset,n/a,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 11:44:16,,1323537872,7/15/2014 11:43:31,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHILDHOOD OCCIPITAL SEIZURES (EBOS) SYMPTOMATIC EPILEPSY,n/a,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 12:05:56,,1323549030,7/15/2014 12:05:33,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],unrecognised syndrome of early onset,n/a,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 12:11:39,,1323550989,7/15/2014 12:11:19,instagc,1.0,18960682,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],had,N/a,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 12:13:53,,1323551852,7/15/2014 12:13:06,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n\a,both listed diseases,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 12:20:51,,1323554666,7/15/2014 12:20:11,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) SYMPTOMATIC EPILEPSY,n/a,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 12:22:37,,1323555314,7/15/2014 12:22:06,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],and three had,different conditions,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 12:59:37,,1323569670,7/15/2014 12:58:46,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Twelve syndrome three,N/A,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 13:11:39,,1323574051,7/15/2014 13:11:29,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221070,7/15/2014 13:41:58,,1323584387,7/15/2014 13:41:09,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,Na,61,118,95,138,-1,RO-has_definitional_manifestation,904993-FS1,Twelve had a previously unrecognised syndrome of early onset BENIGN CHILDHOOD OCCIPITAL SEIZURES (EBOS) and three had SYMPTOMATIC EPILEPSY,BENIGN CHILDHOOD OCCIPITAL SEIZURES,SYMPTOMATIC EPILEPSY
503221071,7/15/2014 09:56:33,,1323466640,7/15/2014 09:56:18,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],treatment,na,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 10:12:43,,1323478001,7/15/2014 10:11:24,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[IS_A],[IS_A],the availability of STA 1 for the treatment of,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 10:37:25,,1323493939,7/15/2014 10:35:59,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[IS_A],[IS_A],ALLERGIC,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 10:51:56,,1323504488,7/15/2014 10:51:31,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],induced,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 11:11:51,,1323518680,7/15/2014 11:11:26,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 11:35:11,,1323532519,7/15/2014 11:34:12,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,[SYMPTOM] [ASSOCIATED_WITH],"[SYMPTOM]
[ASSOCIATED_WITH]",induced,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 11:46:43,,1323539182,7/15/2014 11:45:53,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[OTHER],[OTHER],suppress Der p induced ALLERGIC REACTIONS availability of STA 1 for the treatment of ASTHMA,n/a,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 12:28:07,,1323557322,7/15/2014 12:27:33,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ALLERGIC REACTIONS ALLERGIC ASTHMA,n/a,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 13:05:21,,1323571754,7/15/2014 13:04:17,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],for the treatment of,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 13:13:25,,1323574642,7/15/2014 13:13:09,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 14:20:47,,1323595471,7/15/2014 14:20:12,elite,1.0,28276268,USA,FL,Boynton Beach,99.114.225.45,[TREATS],[TREATS],and treatment of,[TREATS],149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 15:03:20,,1323611328,7/15/2014 15:02:03,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[IS_A],[IS_A],ALLERGIC,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 15:53:12,,1323643659,7/15/2014 15:52:30,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],induced and of,n\a,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 16:12:45,,1323659149,7/15/2014 16:12:20,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[PART_OF],[PART_OF],ALLERGIC,n/a,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221071,7/15/2014 16:23:00,,1323669207,7/15/2014 16:22:40,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was demonstrated,N/A,149,79,163,97,-1,RO-cause_of,900154-FS1,These results showed that STA 1 could effectively suppress the Der p 5 induced ALLERGIC REACTIONS and the availability of STA 1 for the treatment of ALLERGIC ASTHMA was demonstrated in this study.,ALLERGIC ASTHMA,ALLERGIC REACTIONS
503221072,7/15/2014 09:57:13,,1323467237,7/15/2014 09:57:01,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],and,na,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 10:07:21,,1323475109,7/15/2014 10:06:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],were examined in and,N/A,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 10:39:42,,1323495671,7/15/2014 10:37:26,prodege,1.0,27934334,GBR,B9,High Wycombe,86.166.72.139,[NONE],[NONE],N/A,Tourette syndrome abd ADHD are separate conditions with different causes.,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 10:53:07,,1323505196,7/15/2014 10:52:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],examined in and,N/A,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 12:12:06,,1323551126,7/15/2014 12:11:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,both are examples of syndromes that get the same treatment,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 13:30:59,,1323580606,7/15/2014 13:30:43,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],and,N/A,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 13:47:21,,1323586062,7/15/2014 13:46:36,elite,1.0,28276268,USA,CA,San Rafael,98.210.32.37,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],"[DIAGNOSE_BY_TEST_OR_DRUG]
[SIDE_EFFECT]",attention deficit,[DIAGNOSE_BY_TEST_OR_DRUG] [SIDE_EFFECT],279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 14:07:55,,1323591816,7/15/2014 14:07:00,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,none,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 15:02:03,,1323610617,7/15/2014 14:59:56,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[OTHER],[OTHER],genetic factors,N/A,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 15:28:03,,1323624970,7/15/2014 15:27:35,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/a,Separate conditions,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 15:37:41,,1323632041,7/15/2014 15:37:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",TOURETTE SYNDROME HYPERACTIVITY DISORDER,n/a,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 16:14:09,,1323660328,7/15/2014 16:13:42,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"other angry and aggressive behaviors,",n/a,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 17:01:06,,1323713324,7/15/2014 17:00:24,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[NONE],[NONE],none,no relation mentioned,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 17:09:29,,1323721061,7/15/2014 17:09:13,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[PART_OF],[PART_OF],and,N/A,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221072,7/15/2014 17:10:03,,1323721432,7/15/2014 17:08:58,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[ASSOCIATED_WITH] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]",relating to relevant were examined,N/A,279,234,307,251,-1,RO-has_manifestation,906017-FS1,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM III R criteria, as well as other angry and aggressive behaviors, were examined in 1177 TOURETTE SYNDROME (TS) and attention deficit HYPERACTIVITY DISORDER (ADHD) probands, their first degree relatives, and controls.",HYPERACTIVITY DISORDER (ADHD),TOURETTE SYNDROME
503221073,7/15/2014 10:16:04,,1323480103,7/15/2014 10:15:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[IS_A],[IS_A],whether from,N/A,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 11:10:39,,1323517777,7/15/2014 11:09:13,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[CAUSES],[CAUSES],from,N/A,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 11:20:51,,1323524358,7/15/2014 11:20:31,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CAUSES],[CAUSES],from,n/a,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 12:17:35,,1323553273,7/15/2014 12:17:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,[CAUSES],[CAUSES],whether from,N/a,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 13:43:15,,1323584797,7/15/2014 13:42:45,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],greater in patients presenting,na,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 14:03:36,,1323590677,7/15/2014 14:03:07,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],from,n\a,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 14:28:32,,1323597779,7/15/2014 14:28:12,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[CAUSES],[CAUSES],whether from,N/A,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 16:06:23,,1323654131,7/15/2014 16:05:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],from,n/a,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 16:40:23,,1323690223,7/15/2014 16:39:47,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[SYMPTOM],[SYMPTOM],presenting with,N/A,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 16:53:06,,1323704149,7/15/2014 16:52:15,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[CAUSES] [MANIFESTATION] [ASSOCIATED_WITH],"[CAUSES]
[MANIFESTATION]
[ASSOCIATED_WITH]",presenting,NA,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 17:04:19,,1323716611,7/15/2014 17:03:21,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[CAUSES],[CAUSES],from,n/a,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 17:05:49,,1323717925,7/15/2014 17:04:54,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]","or adynamic bone disease,",n/a,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 17:08:38,,1323720354,7/15/2014 17:07:53,tremorgames,1.0,19721342,CAN,ON,Ottawa,99.246.56.98,[ASSOCIATED_WITH],[ASSOCIATED_WITH],from,N/A,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 17:11:53,,1323722816,7/15/2014 17:11:11,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.41,[CAUSES],[CAUSES],from,N/A,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221073,7/15/2014 17:26:11,,1323730699,7/15/2014 17:25:14,clixsense,1,24896327,GBR,V2,Glasgow,94.2.231.4,[MANIFESTATION],[MANIFESTATION],deposited in bone,I didnt,150,181,166,206,1,RO-disease_has_primary_anatomic_site,902178-FS1,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with LOW BONE TURNOVER whether from LOW TURNOVER OSTEOMALACIA or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",LOW BONE TURNOVER,LOW TURNOVER OSTEOMALACIA
503221074,7/15/2014 09:57:53,,1323467870,7/15/2014 09:57:10,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],serum cortisol level was not suppressed,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 10:57:06,,1323507645,7/15/2014 10:56:23,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],level was not suppressed,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 11:02:25,,1323510862,7/15/2014 11:02:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],suppressed,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 11:13:04,,1323519498,7/15/2014 11:12:38,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[CONTRAINDICATES],[CONTRAINDICATES],was not suppressed,n/a,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 11:54:27,,1323544054,7/15/2014 11:53:47,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[SYMPTOM],[SYMPTOM],CUSHING'S SYNDROME AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,n/a,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 13:26:57,,1323579228,7/15/2014 13:26:22,neodev,1.0,18339121,USA,SC,Sumter,173.93.188.194,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]",level,na,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 13:39:31,,1323583615,7/15/2014 13:38:37,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SYNDROME,Na,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 14:00:14,,1323589783,7/15/2014 13:59:18,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CONTRAINDICATES],[CONTRAINDICATES],was not suppressed,n/a,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 14:29:26,,1323598009,7/15/2014 14:29:13,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],suppressed,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 14:31:37,,1323598696,7/15/2014 14:31:27,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],level,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 15:09:12,,1323613839,7/15/2014 15:08:22,quickrewards,1.0,20452113,USA,NY,Port Henry,108.176.206.207,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ADMINISTRATION.,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 15:43:12,,1323636146,7/15/2014 15:41:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CUSHING'S SYNDROME AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,n/a,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 16:20:28,,1323666202,7/15/2014 16:20:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[TREATS],[TREATS],not suppressed,N/A,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 16:47:43,,1323698281,7/15/2014 16:46:44,instagc,1.0,26784981,USA,CA,San Francisco,73.32.39.90,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ADMINISTRATION.,NA,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221074,7/15/2014 16:48:14,,1323698863,7/15/2014 16:46:17,clixsense,1.0,10428985,GBR,N7,Weybridge,81.132.17.135,[NONE],[NONE],N/A,No related terms found.,52,115,69,162,1,RO-may_diagnose,906655-FS1,Although she had no characteristic feature of overt CUSHING'S SYNDROME her serum cortisol level was not suppressed AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION.,CUSHING'S SYNDROME,AFTER AN OVERNIGHT DEXAMETHASONE ADMINISTRATION
503221075,7/15/2014 09:57:34,,1323467547,7/15/2014 09:57:14,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[TREATS],[TREATS],multicenter study,na,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 10:12:19,,1323477813,7/15/2014 10:12:02,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[TREATS],[TREATS],after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 10:22:05,,1323484205,7/15/2014 10:21:22,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TIMOLOL after MYOCARDIAL INFARCTION,Associated With,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 10:46:06,,1323500153,7/15/2014 10:44:38,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[CONTRAINDICATES] [OTHER],"[CONTRAINDICATES]
[OTHER]",after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 11:04:59,,1323512797,7/15/2014 11:04:39,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[TREATS],[TREATS],after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 11:54:19,,1323543996,7/15/2014 11:53:54,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[PART_OF],[PART_OF],study of after,n/a,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 12:17:05,,1323553120,7/15/2014 12:16:29,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],TIMOLOL MYOCARDIAL INFARCTION,n/a,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 12:51:16,,1323566319,7/15/2014 12:51:02,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[CAUSES],[CAUSES],TIMOLOL after MYOCARDIAL INFARCTION,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 12:52:50,,1323566933,7/15/2014 12:52:22,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],study after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 13:07:45,,1323572694,7/15/2014 13:07:32,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[ASSOCIATED_WITH],[ASSOCIATED_WITH],after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 13:15:57,,1323575516,7/15/2014 13:15:33,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[MANIFESTATION],[MANIFESTATION],after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 13:56:06,,1323588523,7/15/2014 13:55:10,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[MANIFESTATION],[MANIFESTATION],after,none,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 14:24:53,,1323596621,7/15/2014 14:24:23,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],of,Na,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 14:28:04,,1323597618,7/15/2014 14:27:52,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],study,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221075,7/15/2014 14:50:07,,1323605872,7/15/2014 14:48:59,prodege,1,22124564,GBR,N5,Lowestoft,90.220.97.157,[ASSOCIATED_WITH],[ASSOCIATED_WITH],after,N/A,49,35,69,42,1,RO-may_treat,907627-FS1,The Norwegian multicenter study of TIMOLOL after MYOCARDIAL INFARCTION,MYOCARDIAL INFARCTION,TIMOLOL
503221076,7/15/2014 09:56:46,,1323466863,7/15/2014 09:56:34,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[SYMPTOM],[SYMPTOM],characterized,na,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 10:10:24,,1323476730,7/15/2014 10:09:56,prodege,1.0,22031444,GBR,B7,Bristol,77.98.139.82,[MANIFESTATION],[MANIFESTATION],are characterized clinically by a pattern of,N/A,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 10:24:06,,1323485368,7/15/2014 10:23:11,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[MANIFESTATION] [SYMPTOM],"[SYMPTOM]
[MANIFESTATION]",OSTEOID OSTEOMAS characterized clinically NOCTURNAL PAIN WHICH IS EXQUISITELY,Manifestation/Symptom,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 11:08:01,,1323515616,7/15/2014 11:06:41,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[MANIFESTATION],[MANIFESTATION],characterized clinically,n/a,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 11:10:00,,1323517320,7/15/2014 11:09:22,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[SYMPTOM],[SYMPTOM],clinically pattern,not applicable,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 11:28:23,,1323528621,7/15/2014 11:27:31,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are characterized clinically by,N/A,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 12:03:41,,1323548215,7/15/2014 12:01:36,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],characterized clinically by a pattern,n/a,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 12:14:07,,1323551935,7/15/2014 12:13:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],are characterized clinically,N/a,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 12:34:44,,1323559689,7/15/2014 12:32:39,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,[SYMPTOM],[SYMPTOM],OSTEOID OSTEOMAS characterized by NOCTURNAL PAIN,N/A,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 13:58:31,,1323589251,7/15/2014 13:57:41,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],characterized clinically by,n/a,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 14:48:58,,1323605445,7/15/2014 14:47:59,prodege,1.0,22124564,GBR,N5,Lowestoft,90.220.97.157,[SIDE_EFFECT],[SIDE_EFFECT],are characterized clinically by a pattern of,N/A,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 14:56:06,,1323608105,7/15/2014 14:55:37,clixsense,1.0,26770238,CAN,ON,London,209.183.157.27,[CAUSES],[CAUSES],characterized clinically by a pattern of,N/A,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 16:24:29,,1323670706,7/15/2014 16:24:14,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized,N/A,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 16:40:54,,1323690730,7/15/2014 16:38:47,clixsense,1.0,21917173,CAN,"","",24.71.41.51,[SYMPTOM],[SYMPTOM],characterized,?,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221076,7/15/2014 16:57:35,,1323709255,7/15/2014 16:56:22,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[CAUSES] [SYMPTOM] [ASSOCIATED_WITH],"[CAUSES]
[SYMPTOM]
[ASSOCIATED_WITH]",clinically by pattern of,n/a,62,0,96,16,1,RO-disease_has_finding,901643-FS1,OSTEOID OSTEOMAS are characterized clinically by a pattern of NOCTURNAL PAIN WHICH IS EXQUISITELY sensitive to salicylates.,NOCTURNAL PAIN WHICH IS EXQUISITELY,OSTEOID OSTEOMAS
503221077,7/15/2014 10:02:15,,1323471467,7/15/2014 10:01:57,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[LOCATION],[LOCATION],usually arises in,N/A,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 10:07:00,,1323474960,7/15/2014 10:06:42,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[LOCATION],[LOCATION],arises in,na,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 11:07:03,,1323514707,7/15/2014 11:06:30,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[LOCATION],[LOCATION],arises in the native,not applicable,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 11:07:20,,1323514968,7/15/2014 11:07:05,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,[LOCATION],[LOCATION],in the,N/A,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 11:44:55,,1323538119,7/15/2014 11:44:18,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[LOCATION],[LOCATION],RENAL CELL CARCINOMA (RCC) KIDNEYS,n/a,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 12:06:21,,1323549128,7/15/2014 12:05:57,clixsense,1.0,6500439,AUS,02,Ingleburn,115.146.65.99,[SYMPTOM],[SYMPTOM],arises in the native,n/a,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 12:25:28,,1323556388,7/15/2014 12:24:59,rewardsspot,1.0,24482174,GBR,H9,London,46.23.68.180,[CAUSES],[CAUSES],CELL CARCINOMA (RCC) KIDNEYS,n/a,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 12:45:23,,1323563779,7/15/2014 12:45:06,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[LOCATION],[LOCATION],in,N/A,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 12:55:13,,1323567699,7/15/2014 12:54:53,clixsense,1.0,20614047,USA,ID,Priest River,174.32.160.124,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],RENAL CELL CARCINOMA,asd,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 13:32:46,,1323581202,7/15/2014 13:31:57,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[LOCATION],[LOCATION],usually arises in,N/A,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 14:25:28,,1323596769,7/15/2014 14:24:55,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in,Na,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 14:27:10,,1323597302,7/15/2014 14:26:56,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CONTRAINDICATES],[CONTRAINDICATES],native,N/A,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 14:32:47,,1323599079,7/15/2014 14:32:34,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[LOCATION],[LOCATION],arises in,N/A,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 16:13:40,,1323659894,7/15/2014 16:13:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in the,n/a,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221077,7/15/2014 16:55:10,,1323706341,7/15/2014 16:54:29,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,[SYMPTOM],[SYMPTOM],usually arises,n/a,71,15,77,35,1,RO-disease_has_primary_anatomic_site,902457-FS1,Posttransplant RENAL CELL CARCINOMA (RCC) usually arises in the native KIDNEYS of renal transplant recipients rather than in the transplanted kidney.,KIDNEYS,RENAL CELL CARCINOMA
503221078,7/15/2014 10:05:35,,1323474140,7/15/2014 10:04:36,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,This is a list with no info on any link between them.,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 10:55:59,,1323507044,7/15/2014 10:55:27,instagc,1.0,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],for,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 11:06:29,,1323514139,7/15/2014 11:05:32,clixsense,1.0,8888883,USA,FL,Orlando,76.26.232.146,[TREATS],[TREATS],for,not applicable,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 11:25:01,,1323526684,7/15/2014 11:24:43,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],for,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 11:30:16,,1323529604,7/15/2014 11:30:03,bitcoinget,1.0,25255063,GBR,V2,Glasgow,86.174.15.198,[TREATS],[TREATS],for schizophrenia,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 11:41:19,,1323536081,7/15/2014 11:40:50,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,[NONE],[NONE],n/a,this passage makes no sense,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 11:46:24,,1323538962,7/15/2014 11:45:25,neodev,1.0,27608448,USA,SC,Graniteville,24.145.86.46,[TREATS],[TREATS],medication for,n/a,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 11:53:09,,1323543385,7/15/2014 11:52:24,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SCHIZOPHRENIA OLANZAPINE,n/a,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 12:38:37,,1323561218,7/15/2014 12:38:01,paiddailysurveys,1.0,11786001,USA,NC,Charlotte,71.28.89.238,[TREATS],[TREATS],OLANZAPINE for schizophrenia,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 13:06:19,,1323572177,7/15/2014 13:06:06,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[TREATS],[TREATS],OLANZAPINE for schizophrenia,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 13:59:38,,1323589618,7/15/2014 13:59:04,prodege,1.0,13795372,CAN,NS,Dartmouth,142.68.155.182,[TREATS],[TREATS],for,none,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 14:26:37,,1323597109,7/15/2014 14:26:04,clixsense,1.0,6621167,USA,"","",66.87.78.142,[ASSOCIATED_WITH],[ASSOCIATED_WITH],learning,Na,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 14:27:49,,1323597560,7/15/2014 14:27:34,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],for,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 14:29:49,,1323598133,7/15/2014 14:29:37,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[MANIFESTATION],[MANIFESTATION],(Cochrane,N/A,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221078,7/15/2014 15:35:19,,1323630217,7/15/2014 15:35:07,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SCHIZOPHRENIA OLANZAPINE,n/a,253,286,265,296,1,RO-may_treat,907749-FS1,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for SCHIZOPHRENIA (Cochrane Review)  OLANZAPINE for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,SCHIZOPHRENIA,OLANZAPINE
503221079,7/15/2014 09:55:45,,1323466007,7/15/2014 09:55:30,clixsense,1.0,27793793,GBR,C5,Chester,151.230.27.155,[ASSOCIATED_WITH],[ASSOCIATED_WITH],approximately 50%,na,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 10:12:01,,1323477647,7/15/2014 10:11:40,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 10:13:29,,1323478477,7/15/2014 10:12:59,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],RASHES rashes.,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 10:14:34,,1323479148,7/15/2014 10:13:40,clixsense,1.0,15189335,GBR,E4,Colchester,5.67.141.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and approximately,na,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 10:23:09,,1323484823,7/15/2014 10:22:06,neodev,1.0,11460728,CAN,BC,Burnaby,70.79.16.165,[IS_A],[IS_A],MALAR LUPUS RASHES DISCOID LUPUS rashes.,Is A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 10:41:29,,1323496777,7/15/2014 10:40:36,elite,1.0,28397222,GBR,Y4,Usk,31.50.223.75,[ASSOCIATED_WITH],[ASSOCIATED_WITH],provided supportive evidence of,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 11:17:08,,1323522011,7/15/2014 11:16:48,prodege,1.0,15439740,AUS,02,Jannali,27.96.208.89,[OTHER],[OTHER],and,n/a,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 11:19:27,,1323523567,7/15/2014 11:18:41,prodege,1.0,7061586,AUS,02,Toongabbie,114.76.177.0,[IS_A],[IS_A],evidence,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 11:35:59,,1323533012,7/15/2014 11:35:29,rewardsspot,1.0,17763704,USA,VA,Manassas,198.7.62.204,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MALAR LUPUS RASHES DISCOID LUPUS,n/a,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 12:28:38,,1323557504,7/15/2014 12:28:11,prodege,1.0,19192508,USA,OK,Broken Arrow,70.177.111.89,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 12:39:28,,1323561610,7/15/2014 12:38:53,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],and,different kinds of rashes,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 13:05:47,,1323571934,7/15/2014 13:05:25,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,[MANIFESTATION] [ASSOCIATED_WITH],"[MANIFESTATION]
[ASSOCIATED_WITH]",and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 13:11:43,,1323574073,7/15/2014 13:10:51,neodev,1.0,12115558,USA,OH,Twinsburg,75.187.196.41,[SYMPTOM],[SYMPTOM],evidence of cutaneous lupus and DISCOID LUPUS rashes.,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 13:33:20,,1323581417,7/15/2014 13:33:07,prodege,1.0,15287417,CAN,ON,Mississauga,209.171.47.69,[OTHER],[OTHER],and,N/A,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
503221079,7/15/2014 13:38:34,,1323583227,7/15/2014 13:37:40,clixsense,1.0,6621167,USA,"","",66.87.78.142,[SIDE_EFFECT],[SIDE_EFFECT],and,Na,172,105,184,123,-1,RO-cause_of,900039-FS1,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of MALAR LUPUS RASHES and approximately 50% of subacute cutaneous and DISCOID LUPUS rashes.,DISCOID LUPUS,MALAR LUPUS RASHES
